



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 5/00, A61K 39/00, 35/14, G01N 33/50</b>		A2	(11) International Publication Number: <b>WO 99/42564</b>
			(43) International Publication Date: 26 August 1999 (26.08.99)
(21) International Application Number: PCT/US99/03763 (22) International Filing Date: 19 February 1999 (19.02.99)  (30) Priority Data: 60/075,356      20 February 1998 (20.02.98)      US 60/077,095      6 March 1998 (06.03.98)      US 60/101,749      24 September 1998 (24.09.98)      US  (71) Applicant: THE ROCKEFELLER UNIVERSITY [US/US]; 1230 York Avenue, New York, NY 10021-6399 (US).  (72) Inventors: ALBERT, Matthew, L.; 500 East 63rd Street, New York, NY 10021 (US). BHARDWAJ, Nina; 114 Upper Mountain Avenue, Montclair, NJ 07042 (US). STEINMAN, Ralph, M.; 62 North Avenue, Westport, CT 06880 (US). INABA, Kayo; Tanaka-Higashihinokuchi-cho 11-2, Sakyo, Kyoto 606-01 (JP).  (74) Agents: SONNENFELD, Kenneth, H. et al.; Morgan & Finnegan, L.L.P., 345 Park Avenue, New York, NY 10154 (US).			(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: APOPTOTIC CELL-MEDIATED ANTIGEN PRESENTATION TO DENDRITIC CELLS  (57) Abstract  This invention relates to methods and compositions useful for delivering antigens to dendritic cells which are then useful for inducing antigen-specific cytotoxic T lymphocytes and T helper cells. This invention also provides assays for evaluating the activity of cytotoxic T lymphocytes. According to the invention, antigens are targeted to dendritic cells by apoptotic cells which may also be modified to express non-native antigens for presentation to the dendritic cells. The dendritic cells which are primed by the apoptotic cells are capable of processing and presenting the processed antigen and inducing cytotoxic T lymphocyte activity or may also be used in vaccine therapies.			
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> </div> <div style="width: 45%;"> <p><b>A</b></p> </div> </div> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> </div> <div style="width: 45%;"> <p><b>B</b></p> </div> </div> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> </div> <div style="width: 45%;"> <p><b>C</b></p> </div> </div>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

° TITLE OF THE INVENTION

**APOPTOTIC CELL-MEDIATED ANTIGEN PRESENTATION TO DENDRITIC CELLS**

5 This invention was made with United States Government support under National Institutes of Health grant AI-39516, AI-13013 and AI 39672. The United States Government has certain rights in this invention.

10 This application claims priority to United States provisional applications Serial No. 60/075,356 filed February 20, 1998, Serial No. 60/077,095 filed March 6, 1998; and Serial No. 60/101,749 filed September 24, 1998 all of which are incorporated herein by reference.

15 FIELD OF THE INVENTION

20 This invention relates to targeted antigen presentation in the immune system. In particular, this invention relates to the use of apoptotic cells to deliver antigens to dendritic cells for induction or tolerization of antigen-specific T cell responses. The apoptotic cell-mediated antigen delivery system described herein has a wide range of preventive, diagnostic and therapeutic applications.

BACKGROUND OF THE INVENTION

30 CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) play a critical role in immune defense against infectious agents, tumors and transplants. Class I-restricted CD8<sup>+</sup> T cells have been implicated in the recognition and destruction of such clinically important targets as HIV-1 (1-3),

- 2 -

o Influenza A (4), malaria (5), cytomegalovirus infected cells (6), Epstein-Barr virus (7), and human melanoma cells (8-9). Therefore, establishing methods for inducing and expanding populations of antigen-specific CD8<sup>+</sup> CTLs remains an important objective in the development of  
5 therapeutic treatments against infectious disease and cancer.

CD8<sup>+</sup> CTLs are activated by antigens which have been processed and presented on major histocompatibility  
10 (MHC) class I molecules on the surface of specialized antigen presenting cells. A number of antigen presenting cells have been identified which activate T cells including macrophages/monocytes, B cells and bone marrow derived dendritic cells. Of these, dendritic cells are  
15 recognized as playing a pivotal role in the initiation of CD8<sup>+</sup> CTL responses (10).

An important feature of dendritic cells is their ability to efficiently process and present antigens on MHC  
20 class I and/or class II molecules. Depending on the antigen processing pathway, dendritic cells are capable of activating distinct populations of CTLs. In the case of influenza virus, for example, it is known that the class I pathway for inducing CD8<sup>+</sup> CTLs requires adequate delivery  
25 of infectious viral antigen into the cytoplasm, whereas the purely endocytic pathway delivers noninfectious virions for presentation only to CD4<sup>+</sup> T helper cells (U.S. 08/282,966). Thus, although dendritic cells efficiently  
30 activate class I-restricted CTLs, access to the MHC class I pathway for induction of CD8<sup>+</sup> T cells normally requires endogenous synthesis of antigen. Accordingly, it is

- important to identify antigen delivery systems which efficiently mediate access of exogenous antigen to the MHC class I-restricted antigen presentation pathway in order to generate antigen-specific CD8<sup>+</sup> T cell responses.

5 Recently, a number of approaches have been reported for delivery of exogenous antigen to the MHC I processing pathway of dendritic cells. These methods include coupling antigens to potent adjuvants (11-15), osmotic lysis of pinosomes after pinocytic uptake of  
10 soluble antigen (16), or insertion of antigen in pH-sensitive liposomes (17). However, these prior approaches still pose a number of limitations on the development of effective therapeutic treatments. For example, Nair et al. report that dendritic cells do not efficiently internalize  
15 antigen-containing liposomes in vivo (18). Further, osmotic lysis of dendritic cell pinocytic vesicles may be difficult to perform in vivo, and may result in inefficient antigen delivery to the MHC class I processing  
20 compartment. Also, the use of powerful adjuvants may be undesirable for some clinical applications.

Pulsing dendritic cells directly with exogenous antigen using whole cells in viable or irradiated forms,  
25 membrane preparations, or antigens purified from natural sources or expressed as recombinant products has also been previously reported (WO 94/02156). These prior methods, however, do not recognize forms of cell death or the processing pathways antigens from dead or dying cells  
30 access in the dendritic cell system.

Rubartelli et al. report that dendritic cells, unlike macrophages, fail to take up opsonized particles or

- necrotic cells in vitro, but can efficiently engulf cells undergoing apoptotic programmed cell death (19). The mechanism of internalization of apoptotic cells by dendritic cells, however, is different than in macrophages, indicating that results in the macrophage system are not necessarily predictive of dendritic cell responses. In addition, Rubartelli et al. does not show presentation of engulfed material and therefore speculates as to the fate of such material.

10

#### SUMMARY OF THE INVENTION

This invention provides highly efficient methods for delivering exogenous antigens to dendritic cells and inducing antigen-specific T cell activation. In particular, the methods described in this invention are directed toward developing therapies for increasing patient immunity to chronic infections and tumors by 1) inducing tumor or infected cells to undergo apoptosis, 2) having the apoptotic tumor or infected cells gain access to phagocytic, maturing dendritic cells, and 3) exposing the apoptotic cell-primed dendritic cells expressing antigen of interest to T cells, in vivo or in vitro, for induction of antigen-specific T cell responses.

25

This invention further provides that the population of donor cells expressing said antigen can be induced to undergo apoptosis using a variety of methods including, but not limited to, viral infection, irradiation with ultraviolet light, gamma radiation, cytokine treatment, or depriving donor cells of nutrients in the cell culture medium. It is also contemplated by

30

35

- this invention that the dendritic cells can be exposed to a preparation of donor apoptotic cell fragments, blebs or bodies rather than whole apoptotic cells.

In another embodiment of this invention, the donor cells can be transfected, transduced or transformed to express foreign antigens prior to induction of apoptosis. A variety of such antigens may be expressed by the donor cells including, but not limited to, viral antigens, tumor antigens, toxins, microbial antigens, and autoimmune antigens.

Accordingly, this invention also provides a method of generating antigen-specific cytotoxic T lymphocytes comprising providing a population of apoptotic cells, or membrane containing fragments thereof, expressing said antigen, exposing dendritic cells to said apoptotic cells for a time sufficient to allow said antigen to be internalized and processed by the dendritic cells, and exposing T lymphocytes in vivo to said dendritic cells for a time sufficient to induce said lymphocytes to become antigen-specific T lymphocytes. This invention further contemplates induction of antigen-specific T lymphocytes in vitro.

In another embodiment of this invention apoptotic cells expressing an antigen to be presented by dendritic cells are administered to an individual in an amount and in a location so as to prime dendritic cells in vivo.

Methods of preventing and treating disease are also provided by this invention which comprises administering to an individual in need of treatment, a

- therapeutically effective amount of dendritic cells which have been primed by apoptotic cells.

In addition to the methods of this invention, this invention also provides dendritic cells which have been primed by apoptotic cells, and in particular, human  
5 dendritic cells which are prepared according to the methods of this invention. This invention further provides transformed apoptotic cells, or a preparation of transformed apoptotic cell fragments, and in particular,  
10 human apoptotic cells which are prepared according to the methods of this invention.

In another embodiment of this invention the apoptotic cell delivery system is reconstituted in vitro  
15 using liposomes comprising antigen and apoptotic cell proteins, factors or ligands which enhance uptake and processing of antigen in dendritic cells.

Based on the results disclosed herein, one may include in a liposome ligands for integrin receptors,  
20 including, but not limited to the  $\alpha_v\beta_5$  and  $\alpha_v\beta_3$  integrin receptors for enhancing uptake and processing of antigens in dendritic cells. An example of such a ligand is lactadherin. Other examples of proteins which may enhance  
25 uptake of apoptotic particles include thrombospondin. Similarly, ligands which bind CD36 may also be used. In a preferred embodiment ligands for both integrin and CD36 would be used.

Heat shock proteins (HSP) may also be included  
30 to facilitate antigen uptake by dendritic cells. For example, HSP 70 family members, especially HSP 70, and HSP 90 members, especially HSP 84 and GP 96 may be used.



- Certain antigens obtained from infectious sources may already be bound to HSPs. Alternatively, antigens may be complexed to HSP ex vivo.

The identification of the  $\alpha_v\beta_5$  integrin receptor as mediating antigen uptake by dendritic cells provides  
5 one with a means of modulating that antigen uptake by either increasing or decreasing the activity of the  $\alpha_v\beta_5$  receptor. Accordingly, this invention provides means for enhancing antigen uptake and processing by dendritic cells  
10 in vitro or in vivo, by adding an  $\alpha_v\beta_5$  ligand to the dendritic cells in conjunction with the antigen to be taken up and processed. Alternatively, one could attenuate the antigen uptake activity of the dendritic  
15 cells by blocking the  $\alpha_v\beta_5$  receptor, or other receptors which are involved in mediating antigen uptake by the dendritic cells.

This invention also includes pharmaceutical compositions for charging dendritic cells comprising a  
20 ligand which activates antigen uptake, such as an  $\alpha_v\beta_5$  ligand, with or without an antigen to be processed and presented by dendritic cells. As used in this invention such ligands may be considered to function as  
25 immunoadjuvants.

This invention also provides methods for modulating T cell responses in vivo or in vitro to induce immunity or tolerance by controlling DC maturation.

30 In one embodiment, T cell immunity can be induced when immature DCs are caused to mature by the addition of appropriate maturation factors after the uptake of apoptotic particles. Examples of maturation

- factors that can be used in this invention include monocyte conditioned medium, TNF- $\alpha$ , IL-1 $\beta$ , IL6, PGE<sub>2</sub>, IFN- $\alpha$ , CD40 ligand, and necrotic cells.

In another embodiment, tolerance can be induced to self or foreign antigens by maintaining DCs in their immature state in the absence of a maturation signal.

It is a general object of this invention to provide a method of using apoptotic cells, or apoptotic cell fragments, to efficiently deliver specific antigens to dendritic cells which then process and present said processed antigens on their surface for stimulation or tolerization of cytotoxic T lymphocytes.

It is another object of this invention to generate antigen-specific cytotoxic T lymphocytes either in vivo or in vitro by using the dendritic cells generated by the methods described herein.

It is also an object of this invention to provide a method of prophylactic or therapeutic treatment for a variety of cancers, autoimmune diseases, and pathogens using the dendritic cells described herein.

#### DESCRIPTION OF FIGURES

Figures 1a, 1b and 1c: Dendritic cells acquire antigen from influenza-infected cells and induce class I-restricted CTLs. Fig.1a,1b. Varying doses of influenza-infected syngeneic monocytes [Fig.1a] and allogeneic HLA-A2.1<sup>+</sup> monocytes were co-cultured with DCs and T cells for 7 days. After 8 to 10 hours, 10<sup>6</sup> T-cells and 3.3 x 10<sup>4</sup> DCs derived from HLA-A2.1<sup>+</sup> were added. On day 7, cytolytic activity was tested using syngeneic influenza-

infected macrophages [Fig.1a] or T2 cells, a HLA-A2.1<sup>+</sup> cell line which lacks the transporters of antigen processing or TAP, pulsed with the immunodominant influenza matrix peptide (35,36) [Fig.1b] as targets. Influenza-infected DCs served as a control in all experiments in order to measure the donor's CTL responsiveness to influenza. Responses varied as a function of the individual's prior exposure to influenza. Background lysis ranged from 0-5% for the uninfected monocytes and 0-20% for the unpulsed T2 cells. Fig.1c. Uninfected syngeneic DCs were co-cultured with influenza-infected allogeneic monocytes for 2 days prior to being used as targets for CTLs. Control targets included influenza-infected syngeneic DCs and influenza-infected allogeneic monocytes. Effector: target ratio = 45:1. These results in Figures 1a,1b and 1c are representative of 8 experiments and the values shown represent the mean from triplicate wells.

Figures 2a and 2b: Antigen transfer is not due to live influenza virus or free peptide. [Fig.2a].  $5 \times 10^4$  infected allogeneic HLA-A2.1<sup>+</sup> monocytes were cultured for 10 hours, after which the media from the wells containing infected monocytes was removed and added to fresh wells containing HLA-A2.1<sup>+</sup> T-cells and DCs [10 hr transfer]. Media from the infected monocyte was also passed through a 0.45 micron filter, prior to addition to wells containing HLA-A2.1<sup>+</sup> T cells and DCs [filter]. Effector:target ration= $30:1$ . [Fig.2b].  $5 \times 10^3$  infected allogeneic (HLA-A2.1 mismatched) monocytes were cultured for 10 hours, after which T-cells and DCs were added to

- 10 -

the wells [filled squares]. Alternatively, the medium from the wells containing infected monocytes (HLA-A2.1 mismatched) was removed and transferred to fresh wells containing T-cells and DCs [stars]. Other cultures were established in which the medium was first spun at 250 x g in a GH-3.8 Beckman Rotor for 10 minutes. The resulting supernatant fraction [up triangle] versus the pellet [down triangle] was added to the T cell and DC containing cultures. After 7 days, cytolytic activities in the T cell populations were determined. T2 cells pulsed with the influenza matrix peptide were used as targets. These results are representative of 3 experiments and the values shown represent the mean from triplicate wells.

Figures 3a, 3b, 3c and 3d: Apoptosis is required for delivery of antigen to DCs. [Fig.3a]. Monocytes were infected with live and heat-inactivated influenza virus. After overnight culture, cells were stained with annexin V-FITC [ann V] and propidium iodide [PI], and analyzed by flow cytometry (FACScan®). Early apoptotic cells are defined by the ann V<sup>+</sup>, PI<sup>-</sup> population (37). [Fig.3b]. Allogeneic HLA-A2.1<sup>-</sup> monocytes were infected with either heat-inactivated, non-replicating influenza virus (15) or with live influenza virus.  $5 \times 10^3$  monocytes were cultured for 10 hours, after which the media from the wells containing the infected monocytes was removed and added to fresh wells containing T cells and uninfected DCs [10 transfer]. Alternatively, the infected monocytes were co-cultured with the T cells and DCs [co-culture]. Heat-inactivated influenza and live influenza-infected DCs 1 served as the

- 11 -

positive controls for the experiment. After 7 days, T cells were tested for cytolytic activity using T2 cells as targets. [Fig.3c]. Apoptosis of influenza-infected monocytes was inhibited using Z-VAD-CHO, an irreversible peptide-aldehyde inhibitor of caspases, the enzymes that are involved in the apoptotic pathway. 1 x 10<sup>4</sup> infected monocytes were exposed to varying doses of Z-VAD and cultured for 10 hours. The media from these wells was then transferred to fresh wells containing 2 x 10<sup>5</sup> T cells and 6.67 x 10<sup>3</sup> DCs. Cytolytic activity was determined as in [Fig.3b]. [Fig.3d]. Cells of the human kidney epithelial 293 cell line (ATCC), were infected with influenza virus, and cultured for 10 hours at 37°C. Apoptosis was then induced by exposure to 60 mJ/cm<sup>2</sup> of UVB irradiation. Necrosis was achieved by incubating the 293 cells in a hypotonic solution for 30 minutes at 37°C, as determined by incorporation of trypan blue. Apoptotic or necrotic 293 cells were co-cultured with T cells and uninfected DCs for 7 days. Cytolytic activity was determined as in [Fig.3b]. Uninfected 293 cells cultured with T cells and DCs failed to induce virus-specific CTLs [data not shown]. These results in Figures 3a-3d are representative of 9 experiments and the values shown represent the mean from duplicate or triplicate wells.

Figures 4a and 4b: Generation of CD8<sup>+</sup> CTLs requires CD4<sup>+</sup> T-cell help and dendritic cells. [Fig.4a]. 5 x 10<sup>4</sup> influenza-infected allogeneic monocytes were co-cultured with DCs and CD8<sup>+</sup> T cells. Highly purified CD8<sup>+</sup> T cells (13) were cultured either alone, 50 U/ml human IL-2 or with CD4<sup>+</sup> T cells. IL-2 was added on days 0 and 3.

- 12 -

0 The ratio of CD8<sup>+</sup>: CD4<sup>+</sup> T cells was 1:3, matching the  
ratio in peripheral blood. Cytolytic activities were  
determined using T2 cells pulsed with the influenza matrix  
peptide as targets. Effector: target ratio =10:1. This  
data is representative of 3 experiments, each testing  
5 various doses of apoptotic monocytes. [Fig.4b].  
Influenza-infected syngeneic monocytes were co-cultured  
with various APCs and bulk T cells. Uninfected DCs,  
uninfected monocytes and mixtures of both were used as the  
APCs. Infected monocytes alone and infected DCs served as  
10 controls for the experiment. Cytolytic responses were  
measured as described. Effector: target ratio= 30:1.

Figures 5a, 5b and 5c: Dendritic cells engulf  
apoptotic monocytes. Influenza-infected monocytes and  
15 uninfected DCs were co-cultured for up to 10 hours.  
[Fig.5a]. Cells were stained by immunofluorescence with  
anti-CD8 [isotype control] or anti-p55 followed by goat  
anti-mouse-FITC and incubation with 4'6' diamidino-2-  
phenylindole (DAPI) [Sigma]. The nucleus of the DCs  
20 [arrows] are lobulated and euchromatic as compared with  
the pyknotic, fragmented nucleus of apoptotic cells [open  
arrows]. DAPI<sup>+</sup> material from an apoptotic cell appears to  
be within the cytoplasm of a p55<sup>+</sup> DC. [Fig.5b]. Electron  
25 microscopy revealed apoptotic material and apoptotic cells  
[AC] within the cytoplasm of glutaraldehyde fixed DCs  
(38). [Fig.5c]: DCs are identified by immuno-electron  
microscopy with anti-CD83 visualized by 10 nm gold beads.  
30 Inset 1 shows the localization of CD83 [arrows] on the  
processes of the DC. Note the double membrane in inset 2  
[arrowheads], which reveals an apparently intact plasma

- 13 -

membrane of the cell. After immuno-labeling the  
° paraformaldehyde fixed DCs, the cell pellet was augmented  
with glutaraldehyde fixed tumor cells [\*].

Figure 6: Apoptotic transfected 293 cells serve  
as antigenic material for 'cross-priming' of CD8<sup>+</sup> T cells.

5

Figure 7: CD8<sup>+</sup> T-cells and not CD4<sup>+</sup> cells are  
responsible for influenza-specific cytotoxicity.

10

Figure 8: Immature DCs phagocytose Influenza  
Infected EL4 cells and stimulate Influenza-specific CTLs.

15

Figures 9A and 9B: Immature DCs, but not mature  
DCs or macrophages cross-present antigenic material from  
apoptotic cells and become targets of antigen-specific  
CTLs. [Fig 9a]. Various populations of HLA-A2.1+  
professional antigen presenting cells (APCs) were co-  
cultured with HLA-A2.1- influenza infected monocytes.  
[Fig. 9b]. Influenza infected CD83<sup>+</sup> DCs serve as better  
targets in a CTL than infected CD83-DCs or CD14<sup>+</sup>  
20 macrophages. Controls included infected and uninfected  
APCs. HLA-A2.1- monocytes were also tested as targets to  
demonstrate the absence of lysis when using a mis-matched  
target. Effector : Target Ratios = 45:1 and 15:1.

25

Figures 10A, 10B, 10C, 10D and 10E: Development  
of MHC-peptide complexes consisting of a B cell derived I-  
E $\alpha$  peptide and DC-derived, I-A<sup>b</sup> MHC II products.

30

[Fig 10A]: C57BL/6, I-1<sup>b</sup> DCs were cultured 20  
hrs with no peptide, with 10  $\mu$ M preprocessed peptide, or  
with 2x10<sup>6</sup> B blasts from H-2d BALB/C [I-E<sup>+</sup>] or H-2b

35

° C57BL/6 [I-E<sup>-</sup>] mice. The cultures were labeled with biotin Y-Ae antibody that recognizes the complex of I-Ab and I-E peptide [y-axis] and CD86 costimulator. The CD86-rich DCs [black arrows] acquire I-E peptide. No labeling is seen with an IgG2b isotype control to Y-Ae [bottom row].

5 [Fig 10B]: As in Fig 10a, but DC-BALB/C blast co-cultures [top] or DCs only [bottom] were labeled with other mAbs to show that CD11c<sup>+</sup> I-Ab<sup>+</sup> I-Ad<sup>-</sup> DCs selectively acquired Y-Ae [arrows].

10 [Fig 10C]: As in Fig. 10a, C57BL/6 DCs were cultured for the indicated times with different doses of I-E $\alpha$  peptide or  $2 \times 10^6$  B blasts from BALB/C mice and double labeled for Y-Ae and CD86. Y-Ae signals [Mean Fluorescence Index] are shown for CD86<sup>+</sup> mature DCs.

15 [Fig 10D]: As in Fig. 10a, but graded doses of B blasts [4 days LPS stimulation] and small B cells were compared as a source of I-E $\alpha$  peptide.

20 [Fig 10E]: As in Fig. 10a, but the DCs were sorted from the 20hr cultures of DCs with peptide or B blasts and used to stimulate IL-2 production [3H-thymidine uptake] from a T-T hybridoma specific for a comparable epitope to the Y-Ae monoclonals.

25 Figures 11A, 11B, 11C and 11D: Antigen transfer requires cellular processing and occurs from xenogenic cells.

30 [Fig 11A]: To rule out transfer of peptide from B cells to DCs, B blasts were separated from immature DCs [6 day mouse bone marrow cultures] by a Transwell filter or added to mature DCs, isolated as single nonadherent



- 15 -

cells from day 8 mouse marrow cultures [methods].

[Fig 11B]: Y-Ae epitope formation is blocked by  $\text{NH}_4\text{Cl}$ . DCs were cultured 20h with B blasts with or without  $\text{NH}_4\text{Cl}$  at 5-20 mM. The cultures were stained for Y-Ae and CD86.

[Fig 11C]: EBV-transformed human B cell lines [0, 0.5 or 5 cells/DC; frequency plots, top] or human monocytes [3 cells/DC; dot blots bottom] serve as a source of I-E $\alpha$  peptide. The monocytes were untreated, subject to freeze thawing, or induced to apoptose by infection with influenza [monocytes-flu] or by UV light [not shown].

[Fig 11D]: Development of MHC-peptide complexes consisting of a B cell-derived I-E $\alpha$  peptide and DC-derived, I-A<sup>b</sup> MHC II products. EBV-transformed human B cells lines (3 cells/DC; necrotic and apoptotic) served as a source of I-E $\alpha$  peptide for mouse DCs. An isotype-matched IgG2b antibody was used as a control for the specific Y-AE labeling that developed on the CD86-rich DCs.

Figures 12A, 12B and 12C: Antigen transfer is preceded by phagocytosis. (A) Top, the formation of Y-Ae after 20 h of DC-B blast co-culture with or without 20 mM  $\text{NH}_4\text{Cl}$ . The DCs then were sorted as double positive for PE-CD11c and FITC-CD86, or in a second experiment, just FITC-CD86<sup>+</sup>, and cultured for 12 h without  $\text{NH}_4\text{Cl}$  (bottom). Y-AE (biotin Y-Ae followed by CyChrome-Avidin) quickly regenerated in DCs that had been blocked by  $\text{NH}_4\text{Cl}$ . No Y-Ae was found in saponin-permeabilized samples of  $\text{NH}_4\text{Cl}$ -treated cultures. (B) Immature DCs were cultured with or

- 16 -

without 20 mM  $\text{NH}_4\text{Cl}$  and 10  $\mu\text{M}$  preprocessed I-E peptide for 15 h, and then Y-Ae levels were measured on the FACS<sup>®</sup>. CD86 (not shown) and Y-Ae epitope formed in the presence of  $\text{NH}_4\text{Cl}$ .

[Fig 12C]. Same as Fig. 12A, but the sorted DCs were used to stimulate IL-2 release from a T-T hybrid specific for the I-A<sup>b</sup>/Ep complex [IL-2 monitored by DNA synthesis in test T blasts]. If the DCs were cultured with B blasts in the absence of  $\text{NH}_4\text{Cl}$  [ ], there is strong T cell stimulation, even if the DCs were fixed. However, if the DCs were cultured with B blasts and  $\text{NH}_4\text{Cl}$  [ ], then there is regeneration of the T cell epitope if the DCs are not fixed prior to the 24 hr culture with T cells [compare left and right].

Figures 13A and 13B: Antigen transfer to DCs in vivo.

[Fig. 13A]:  $2 \times 10^6$  mature, marrow-derived, H-2d DCs were injected into the foot pads of H-2b mice. 2 days later, sections of the popliteal nodes were stained for Y-Ae [blue] and B220 B cell marker [brown] and photographed at low and high power [50 and 200X]. Blue dendritic profiles were scattered throughout the T cell areas.

[Fig 13B]: As in Fig. 13A, but cell preparations enriched in DCs were examined by FACS. Several mouse strains were tested as donors and recipients of the marrow-derived DCs. F1 mice [left column] were used as a positive control. The cells were double labeled for Y-Ae or isotype matched control mAb [y-axis] and for different markers [x-axis]. Y-Ae<sup>+</sup> DCs [black] and B cells [white] are arrowed.

- 17 -

[Fig 13C]: As in B, but the DCs were from B6.I-E  
transgenic (right) or B6 mice (left). Processing by host  
CD11c<sup>+</sup> DCs to form the Y-Ae epitope occurs when the donor  
and recipient DCs differ only in terms of I-E expression.

Figures 14A and 14B: Immature but not mature  
dendritic cells efficiently phagocytose apoptotic cells.

Freshly isolated, blood monocytes were infected  
with live influenza A, PR/8 [Spafas Inc.], labeled with  
the PKH26-GL fluorescent cell linker compound [Sigma  
Biosciences], and incubated at 37 °C for 6-8 hours  
allowing apoptosis to occur. Macrophages, immature DCs and  
mature DCs were dyed with PKH67-GL and added to the  
culture wells containing the apoptotic monocytes at a  
ratio of 1:1. Cells were analyzed by FACScan® where double  
positive cells indicate uptake of the apoptotic cells by  
the various APCs [panels iii., vi., ix]. We used the  
various APCs alone to establish the proper settings  
[panels i., iv., vii.] Note, as the forward scatter of the  
APCs increased, the dying monocytes were excluded from the  
established region [panels ii., v., viii.]. After 2 hr.,  
80% of the macrophages 50% of the immature DCs, and less  
than 10% if the mature DCs had engulfed the apoptotic  
monocytes [A]. In an independent experiment, macrophages  
[squares], immature DCs [diamonds] and mature DCs  
[circles] were prepared and co-cultures with apoptotic  
monocytes were established as described above, and FACS®  
was performed at various time points. Percent phagocytosis  
was calculated based on the number of double positive  
cells [B].

° Figure 15: Low temperature, Cytochalasin D and  
ETDA block phagocytosis of apoptotic cells by immature  
DCs.

Apoptotic monocytes and immature DCs were  
prepared as described. Immature DCs were pre-incubated at  
4° C [A], in the presence of varying concentrations of  
5 Cytochalasin D [B], or EDTA [C] for 30 minutes. Apoptotic  
monocytes were then added to the DC cultures at 4° C [A]  
or 37° C [B,C]. FACS® analysis was performed after 1-2  
hrs. Data shown in Figure 2 are representative of 5  
10 independent experiments in which influenza infected  
monocytes or UVB irradiated HeLa cells were sources of  
apoptotic food for the immature DCs. Percent inhibition  
+/- standard deviation for these experiments were: 4° C,  
15 85% +/- 7%; 10 µM Cytochalasin D, 69% +/- 3%; and 2 mM  
EDTA, 76% +/- 14%.

Figure 16: Immature DCs engulf influenza  
infected monocytes.

20 Influenza infected apoptotic monocytes were co-  
cultured with immature DCs for 1 hr after which the cells  
were adhered to a cover slip and fixed with acetone.  
Immunofluorescence was performed with anti-influenza  
nucleoprotein antibodies [NP] and Texas red conjugated  
25 goat anti-mouse IgG; and biotinylated anti-HLA-DR [DR]  
followed by FITC conjugated streptavidin. Large arrowhead  
indicates apoptotic cell outside the DC prior to  
engulfment. Small arrows indicate apoptotic material  
30 derived from the influenza infected monocytes within DR<sup>+</sup>  
vesicles of the DC. These image were not generated on a  
confocal scope, so the structures of the DC underlying the

apoptotic cell can be seen.

Figures 17A and 17B: Immature DCs but not mature DCs nor macrophages cross-present antigenic material derived from apoptotic cells.

Various populations of HLA-A2.1<sup>+</sup> antigen presenting cells [APCs] were co-cultured with HLA-A2.1<sup>-</sup> influenza infected monocytes. After 12 hrs, the APCs were loaded with <sup>51</sup>Cr and used as targets for HLA-A2.1<sup>+</sup> influenza-reactive CTL lines. Mature DCs were isolated by labeling with the DC-restricted marker CD83, followed by cell sorting on the FACSsort<sup>®</sup> [Becton Dickinson]. Immature DCs were CD14<sup>-</sup> and sorted by FACSsort<sup>®</sup> as a CD83<sup>-</sup> population. Mature macrophages were generated by culturing an adherent mononuclear cell fraction in a Teflon beaker for 9 days. Effector : Target Ratios = 45:1 and 15:1 [A]. Controls included infected and uninfected mature DCs, immature DCs and macrophages. The HLA-A2.1<sup>-</sup> monocytes used as a source of apoptotic material were also tested as targets to demonstrate the absence of lysis when using a mis-matched target. Effector : Target Ratios = 45:1 and 15:1. Results are representative of 3 experiments and the values shown represent the mean of triplicate wells [B].

Figure 18: Intracellular but not extracellular CD83 expression distinguishes immature DCs from mature DCs and macrophages.

Macrophages [A], immature DCs [B] and mature DCs [C] were prepared as previously described. Cells were incubated with anti-CD83, a DC maturation marker, either untreated or post-saponin treatment. The latter

- permeablized the cells allowing for intracellular staining. Cells were then labeled using a PE-conjugated GAM-Ig [Biosciences] A control isotype matched antibody was used.

5                   Figures 19A, 19B, and 19C: Protein and mRNA expression of  $\alpha_v\beta_5$  and CD36 are down regulated during DC maturation.

10                   Immature DCs [A] and mature DCs [B] were incubated with anti- $\alpha_v\beta_3$  [clone 23C6, Pharmingen], anti-CD36 [clone FA6, obtained from the Vth international workshop on leukocyte differentiation antigens], or anti- $\alpha_v\beta_5$  [clone P1F6, Chemicon], followed by PE-conjugated GAM-Ig [Biosciences]. All cells were analyzed by FACScan®.

15                   [C] RNA was purified from highly purified sorted cell populations of immature and mature DCs as previously described. RT-PCR was carried out and after 30 cycles of PCR the distinct bands for  $\beta_3$ ,  $\beta_5$  and CD36 could be seen in the immature DCs [lane 1]. In mature DCs only a faint band

20                   for CD36 and no band for  $\beta_5$  could be visualized [lane 2] indicating minimal mRNA. In contrast, a band was evident for  $\beta_3$  in the mature DCs. Note, the doublet for  $\beta_3$  is an artifact in this particular exposure and does not indicate

25                   two unique bands [lane 2]. As a positive control, extracts from Bowes melanoma cells were run, which are known to express  $\beta_3$  and CD36 (29) [lane 3]. As negative control, the Bowes melanoma cells were run in the absence of a

30                   reverse transcriptase [lane 4].

Figures 20A and 20B: Direct inhibition of phagocytosis by anti- $\alpha_v\beta_5$  and anti-CD36 antibodies.

- 21 -

HeLa cells were labeled with PKH26-GL, followed by irradiation using a 60UVB lamp [Derma Control Inc.], calibrated to provide  $240 \text{ mJ cm}^{-2}$  in 2 minutes, sufficient for the induction of apoptosis. After 6-8 hours immature DCs dyed with PKH67-GL and pre-treated with  $50 \text{ } \mu\text{g /ml}$  of various monoclonal antibodies for 30 minutes were added to the wells containing apoptotic HeLa cells. 45-60 minutes later, cells were analyzed by FACS® for double positive cells. Phagocytic uptake is reported as a percentage of untreated cells. Maximal phagocytosis ranged from 44 - 52%. Results from three experiments were averaged and means plotted + SD. Similar results [data not shown] were obtained when apoptotic monocytes were used [A]. Immature DCs were incubated with red fluorescent latex beads at  $37^\circ \text{C}$  [squares],  $4^\circ \text{C}$  [diamonds], or at  $37^\circ \text{C}$  in the presence of  $50 \text{ } \mu\text{g/ml}$  anti- $\alpha\beta_5$  [circles], anti- $\alpha_v$  [triangles]. The results shown indicate percent phagocytosis over background [B].

Figures 21A, 21B, 21C, 21D and 21E: DCs phagocytose apoptotic cells and necrotic cells. 293 cells were labeled red with the PKH26 GL fluorescent cell linker and induced to undergo apoptosis via UVB irradiation, or necrosis via repeated freezing and thawing. Immature DCs were dyed green with PKH 67-GL and then co-cultured with the apoptotic and necrotic cells for three hours at  $4^\circ$  or  $37^\circ \text{C}$  at a ratio of 1:1. Cells were analysed by FACScan where double positive cells indicate uptake of the apoptotic and necrotic cells by the DCs. Dot blots are gated on the FL1 high positive cells [DCs] thus excluding

- 22 -

- the dead 293 cells from the analysis. [A] Green dyed DCs and red dyed apoptotic [293 UV] and necrotic [293 FT] cells alone. [B] Uptake of apoptotic and necrotic cells by immature DCs; [C] Uptake of apoptotic and necrotic cells by mature DCs. The results shown are representative of ten different experiments. [D] Uptake of FITC labeled beads and CD83 expression by immature DCs. [E] Uptake of FITC labeled beads by immature DCs which were then induced to mature via MCM.

10                   Figures 22A, 22B, 22C, 22D, 22E and 22F: DCs exhibit a mature phenotype following exposure to necrotic but not apoptotic cells. [A] Apoptotic or necrotic BLCL were co-cultured with DCs at ratios of 1:2 or 1:5. After 15 48 hours, the DCs were stained extracellularly for CD83 and intracellularly for CD83 and DC-LAMP (27). [B,C] DCs were co-cultured with apoptotic or necrotic cells at a ratio of 1:2 for 48 hours and then stained extracellularly 20 for CD83 and intracellularly for DC-LAMP. Values represent the averages of the geometric mean indices from three or more experiments. Arrowbars mark the standard deviation. Isotype matched antibodies served as controls in all experiments [data not shown]. [D] Immature and mature DCs 25 were stained with monoclonal antibodies to CD83, CD86, CD40 and HLA-DR. Apoptotic or necrotic cell lines [E] or their respective supernatants [F] were added to immature DCs. After 48 hours the DC were stained with monoclonal 30 antibodies to CD83, CD86, CD40 and HLA-DR. Values represent the averages of the geometric mean indices from three or more experiments. Arrowbars mark the standard deviation. Isotype matched antibodies served as controls



- in all experiments [data not shown].

Figures 23A and 23B: DCs gain heightened T cell stimulatory capacity after exposure to necrotic but not apoptotic cells. Apoptotic or necrotic cell lines were added at various ratios to day 5 or 6 immature DCs. After 48 hours of co-culture, the DCs were assayed for their T cell stimulatory capacity. [A] DCs were irradiated with 3000 rad using a cesium irradiator [Ce 57 ] prior to addition to syngeneic T cells and 0.1ng/ml SEA. After 3 days, 4 $\mu$ ci/ml <sup>3</sup>H-Thymidine was added for 16 hours. [B] After coculture with apoptotic or necrotic cells, or their respective supernatants, DCs were fixed with 1% paraformaldehyde for 30 min at 4 °C, washed extensively, and added in graded doses to 2 x 10<sup>5</sup> allogeneic T cells. After 4 days 4 uci/ml <sup>3</sup>H-Thymidine was added for 16 hours. Immature and MCM matured DCs served as controls. Results are representative of three or more experiments and the values shown represent the mean of triplicate wells.

#### DETAILED DESCRIPTION OF THE INVENTION

This invention relates to methods of delivering antigens to dendritic cells for processing and presentation to T lymphocytes. In particular, this invention relates to the use of apoptotic cells for the packaging and delivery of exogenous antigen to the MHC class I presentation pathway of dendritic cells for stimulation or tolerization of class I-restricted CD8<sup>+</sup> T cells. The apoptotic cell-activated dendritic cells and

- 24 -

- antigen-specific T cells produced according to the method of this invention may be used for various immunological interventions for the prevention and treatment of disease.

For the purpose of a more complete understanding of the invention, the following definitions are described herein:

The term "apoptosis" means non-necrotic cell death, which can occur under a variety of conditions including programmed cell death, exposure to ionizing and UV irradiation, activation of fas and other tumor necrosis factor receptor-related pathways, and drugs. Apoptosis is characterized by, inter alia, formation of "blebs" and vesicles at the plasma membrane, cell shrinkage, pyknosis, and increased endonuclease activity (20-21). Specific markers for apoptosis include, but are not limited to, annexin V staining, propidium iodide staining, DNA laddering, staining with dUTP and terminal transferase [TUNEL].

The term "apoptotic cell" means any cell expressing a native or foreign antigen undergoing apoptosis due to any condition, including those which ususally are associated with causing neurosis. Thus, an apoptotic cell is identified based on its characteristics described above rather than any method used leading to cell death. Similarly, the term "apoptotic cell fragments" means apoptotic cell material, bodies, blebs, vesicles, or particles other than whole apoptotic cells which contain antigen.

The term "necrosis" means a form of cell death resulting from irreversible trauma to cells typically

- 25 -

- caused by osmotic shock or exposure to chemical poison, and is characterized by marked swelling of the mitochondria and cytoplasm, followed by cell destruction and autolysis (22).

5           The term "donor cell" means the apoptotic cell that delivers antigen to dendritic cells for processing and presentation to T cells.

10           The phenomenon of "cross-priming" occurs when antigens from donor cells are acquired by the host APCs such as dendritic cells and are processed and presented on MHC molecules at the surface of the APC for activation of antigen-specific T cells.

15           The phenomenon of "cross-tolerance" occurs when antigens from donor cells are acquired by host dendritic cells and are presented under conditions that are non-inflammatory (lack of inflammation or other maturation stimuli) so as to cause antigen-specific unresponsiveness in T cells.

20           The term "antigen" means all, or parts thereof, of a protein or peptide capable of causing an immune response in a vertebrate preferably a mammal. Such antigens are also reactive with antibodies from animals immunized with said protein. The potent accessory  
25           function of dendritic cells provides for an antigen presentation system for virtually any antigenic epitope which T lymphocytes are capable of recognizing through their specific receptors. Example 1, infra, demonstrates  
30           how dendritic cells can present viral antigen after acquisition from donor cells undergoing apoptosis, and effectively activate CTL responses.

35

° Sources of Dendritic Cells.

The dendritic cells used in this invention can be isolated as described herein or by methods known to those skilled in the art. In a preferred embodiment, human dendritic cells are used from an appropriate tissue source, preferably blood or bone marrow.

Mature dendritic cells can also be obtained by culturing proliferating or non-proliferating dendritic cell precursors in a culture medium containing factors which promote maturation of immature dendritic cells to mature dendritic cells. Steinman et al. United States Patent 5,851,756 and United States applications Application 08/600,483 (WO 97/29182) report methods and compositions for obtaining dendritic cells and are incorporated herein by reference.

The dendritic cell precursors, from which the immature dendritic cells for use in this invention are derived, are present in blood as PMBCs. Although most easily obtainable from blood, the precursor cells may also be obtained from any tissue in which they reside, including bone marrow and spleen tissue. When cultured in the presence of cytokines such as a combination of GM-CSF and IL-4 or IL-13 as described below, the non-proliferating precursor cells give rise to immature dendritic cells for use in this invention.

Culture of Pluripotential PMBCs to Produce Immature Dendritic Cells.

Dendritic cell development can be divided into 4 stages: 1) a proliferating progenitor that can be either dendritic cell committed or uncommitted and capable of

- maturing to a nondendritic cell, 2) a non-proliferating precursor like the blood monocyte that does not show dendritic cell properties but is the starting population for many clinical studies, 3) an immature dendritic cell which has properties and commitment to become a dendritic cell, e.g. specialized antigen capture mechanisms including apoptotic cells for presentation, and MHC rich compartments, and 4) finally, the mature T cell stimulatory dendritic cell.
- Cultures of immature dendritic cells, i.e. antigen-capturing phagocytic dendritic cells, may be obtained by culturing the non-proliferating precursor cells in the presence of cytokines which promote their differentiation. A combination of GM-CSF and IL-4 at a concentration of each at between about 200 to about 2000 U/ml, more preferably between about 500 and 1000 U/ml, and most preferably about 800 U/ml (GM-CSF) and 1000 U/ml (IL-4) produces significant quantities of the immature, i.e. antigen-capturing phagocytic dendritic cells, dendritic cells. Other cytokines or methods known in the art which efficiently generate immature dendritic cells may be used for purposes of this invention. Examples of other cytokines which promote differentiation of precursor cells into immature dendritic cells include, but are not limited to, IL-13. Maturation of dendritic cells requires the addition to the cell environment, preferably the culture medium, of a dendritic cell maturation factor which may be selected from monocyte conditioned medium and/or factors including TNF- $\alpha$ , IL-6, IFN- $\alpha$ , and IL-1- $\beta$ . Alternatively, a mixture of necrotic cells or necrotic cell lysate may be

- 28 -

- added to induce maturation.

#### Co-culture of Dendritic Cells with Apoptotic Cells

Apoptotic cells may be used to deliver antigen to either immature or mature dendritic cells, either  
5 freshly isolated or obtained from in vitro culture. In a preferred embodiment, apoptotic cells comprising an antigen are co-cultured with immature dendritic cells for a time sufficient to allow the antigen to be internalized by the immature dendritic cells. These immature dendritic  
10 cells are then caused to mature by the addition of a maturation factor to the culture medium. The matured dendritic cells expressing processed antigen on their surface are then exposed to T cells for potent CTL  
15 induction.

In another embodiment, apoptotic cells may be used to deliver antigen to mature dendritic cells through surface receptors that enhance internalization of the  
20 apoptotic cells.

In another embodiment, apoptotic cells may be used to deliver antigen to immature dendritic cells that are maintained as immature dendritic cells as a means of efficiently modulating T cell tolerance or immunity in  
25 situ.

In a preferred embodiment, peripheral blood mononuclear cells [PBMCs] can be isolated from blood by sedimentation techniques. T cell-enriched [ER<sup>+</sup>] and T cell-depleted [ER<sup>-</sup>] populations can be prepared by  
30 rosetting with neuraminidase treated sheep red blood cells. Dendritic cells are prepared from the ER<sup>-</sup> cells (Steinman et al. Application Serial No. 08/600,483) as

35

- 29 -

- discussed above and are preferably cultured for 7 days to 10 days in the presence of GM-CSF and IL-4. On about day 7 through 10, apoptotic cells can be co-cultured with the dendritic cells and the dendritic cells caused to mature over the next four days with the addition of monocyte conditioned medium, a signal for maturation.

Besides monocyte conditioned medium, a combination of cytokines may be used to induce maturation of the immature dendritic cells. Examples of cytokines which may be used alone or in combination with each other include, but are not limited to, TNF- $\alpha$ , IL-1 $\beta$ , IL-6, IFN- $\alpha$  and necrotic cells.

The apoptotic cell-activated dendritic cells made according to the method described above are the most efficient for induction of CTL responses. Delivery of antigen to mature dendritic cells, or alternatively, immature dendritic cells that are not caused to mature in vitro, is also within the scope of this invention.

The apoptotic cells useful for practicing the method of this invention should efficiently trigger antigen internalization by dendritic cells, and once internalized, facilitate translocation of the antigen to the appropriate antigen processing compartment.

In a preferred embodiment, the apoptotic cells, or fragments, blebs or bodies thereof, are internalized by the dendritic cells and targeted to an MHC class I processing compartment for activation of class I-restricted CD8<sup>+</sup> cytotoxic T cells.

In another embodiment, the apoptotic cells can be used to activate class II-restricted CD4<sup>+</sup> T helper

- 30 -

cells by targeting antigen via the exogenous pathway and charging MHC class II molecules. Apoptotic cells, blebs and bodies are acquired by dendritic cells by phagocytosis. When a population of CD4+ cells is co-cultured with apoptotic cell-primed dendritic cells, the CD4+ T cells are activated by dendritic cells that have charged their MHC class II molecules with antigenic peptides. The apoptotic cell-charged dendritic cells of this invention activate antigen-specific CD4+ T cells with high efficiency.

For purposes of this invention, any cell type which expresses antigen and is capable of undergoing apoptosis can potentially serve as a donor cell for antigen delivery to the potent dendritic cell system. Examples of antigen that can be delivered to dendritic cells by donor cells include, but are not limited to, viral, bacterial, protozoan, microbial and tumor antigens as well as self-antigens. Preferred antigens for priming dendritic cells in vitro or in vivo are derived from influenza virus, malaria, HIV, EBV human papilloma virus (including both EBV-associated and EBV-unassociated lymphomas), CMV, renal cell carcinoma antigens, and melanoma antigens. In addition, self antigens that are targets of autoimmune responses can be delivered to dendritic cells e.g. insulin, histones, GAD.

For purposes of this invention the population of donor cells expressing antigen can be induced to undergo apoptosis in vitro or in vivo using a variety of methods known in the art including, but not limited to, viral infection, irradiation with ultraviolet light, gamma



◦ radiation, cytokines or by depriving donor cells of nutrients in the cell culture medium. Time course studies can establish incubation periods sufficient for optimal induction of apoptosis in a population of donor cells. For example, monocytes infected with influenza virus begin to express early markers for apoptosis by 6 hours after infection. Examples of specific markers for apoptosis include Annexin V, TUNEL+ cells, DNA laddering and uptake of propidium iodide.

Those skilled in the art will recognize that optimal timing for apoptosis will vary depending on the donor cells and the technique employed for inducing apoptosis. Cell death can be assayed by a variety of methods known in the art including, but not limited to, fluorescence staining of early markers for apoptosis, and determination of percent apoptotic cells by standard cell sorting techniques.

In one embodiment, donor cells are induced to undergo apoptosis by irradiation with ultraviolet light. Depending on the cell type, typically exposure to UV light (60 mjules/cm<sup>2</sup>/sec) for 1 to 10 minutes induces apoptosis. This technique can be applied to any cell type, and may be most suitable for a wide range of therapeutic applications. The apoptotic donor cells expressing an antigen of interest on their surface could then be used to prime dendritic cells in vitro or in vivo.

In another embodiment, donor cells are induced to undergo apoptosis by administering a drug such as which induces apoptosis. This technique can also be applied to any cell type, and is also suitable for a wide range of

- therapeutic applications.

In another embodiment, donor cells are induced to undergo apoptosis by infection with influenza virus. These apoptotic cells which express viral antigens on their surface could then be used to prime dendritic cells  
5 in vitro or in vivo. The apoptotic cell-activated dendritic cells may then be used to activate potent influenza-specific T cells.

In another embodiment, tumor cells may be  
10 obtained and caused to undergo apoptosis. These apoptotic tumor cells, or tumor cell lines, could then be used to deliver tumor antigen to dendritic cells in vitro or in vivo. Once isolated, the tumor cells could be treated  
15 with collagenase or other enzymes which facilitate cell dissociation for culturing. The apoptotic cell-activated dendritic cells may then be used as cancer therapeutic agents by activating the immune system to specifically target the tumor cells.

In another embodiment of the invention, the  
20 donor cells can be transfected, transduced or transformed to express foreign antigens prior to induction of apoptosis. In this manner dendritic cells may be loaded  
25 with antigens not typically expressed on the donor cell. In addition, delivery of antigens via xenotransfer is also contemplated. These methods can be accomplished using standard techniques known in the art.

A variety of possible antigens can be used in  
30 this invention including, but not limited to, bacterial, parasitic, fungal, viral, and tumor antigens of cellular or viral origin. Preferred antigens include influenza

- 33 -

- virus, malaria, HIV, EBV, human papilloma virus, CMV, renal cell carcinoma antigens, and melanoma antigens. In addition, self antigens that are targets of autoimmune responses or other antigens for which it is desired to attenuate an immune response can be expressed on donor  
5 cells using any of the aforementioned methods.

Once donor cells expressing either native or foreign antigen have been induced to undergo apoptosis they can be contacted with an appropriate number of  
10 dendritic cells in vitro or in vivo. The ratio of apoptotic cells to dendritic cells may be determined based on the methods disclosed in Example 1 or Example 6, infra. For most antigens a ratio of only about 1-10 donor cells to 100 immature dendritic cells is suitable for priming  
15 the dendritic cells. Higher numbers of apoptotic cells are preferred if mature dendritic cells are to be primed, preferably 100 to 1000 donor cells to mature dendritic cells.

20 The population of apoptotic cells should be exposed to the dendritic cells for a period of time sufficient for the dendritic cells to internalize the apoptotic cell, or apoptotic cell fragments. Efficiency of cross-priming or cross-tolerizing dendritic cells can  
25 be determined by assaying T cell cytolytic activity in vitro or using dendritic cells as targets of CTLs. Other methods known to those skilled in the art may be used to detect the presence of antigen on the dendritic cell  
30 surface following their exposure to apoptotic donor cells. Moreover, those skilled in the art will recognize that the length of time necessary for an antigen presenting cell to

- phagocytose apoptotic cells, or cell fragments, may vary depending on the cell types and antigens used.

An important feature of the dendritic cells of this invention is the capacity to efficiently present antigens on both MHC class I and class II molecules.

5 Apoptotic donor cells, blebs, bodies or fragments thereof, are acquired by dendritic cells through the exogenous pathway by phagocytosis and as a result also efficiently charge MHC II molecules. CD4+ T cells may be activated by the dendritic cells presenting antigenic peptide which is

10 complexed with MHC II using the method according to this invention, since it is known in the art that dendritic cells are the most potent inducers of CD4+ helper T cell immunity. CD4+ T cells can provide critical sources of

15 help, both for generating active CD8+ and other killer T cells during the acute response to antigen, and for generating the memory that is required for long term resistance and vaccination. Thus, by using apoptotic cells

20 to charge MHC class I and/or II products, efficient T cell modulation in situ can be achieved.

In a preferred embodiment both apoptotic and necrotic donor cells are used to prime dendritic cells.

25 Preferably immature dendritic cells are contacted with the donor cells and both class I and II MHC receptors become optimally charged with antigen. In addition, the dendritic cells are matured by the presence of the necrotic cells which also contributes to MHC class II

30 loading.

A novel aspect of this invention is the use of apoptotic cells to prime dendritic cells with antigen. An

- 35 -

◦ important advantage of the apoptotic cell system is that even poorly defined or undefined antigens can be routed to the appropriate antigen processing compartment of the dendritic cells to generate antigen-specific T cell responses. Moreover, dendritic cells can be charged with multiple antigens on multiple MHCs to yield poly or oligoclonal stimulation of T cells. Thus, since the starting material can be obtained from virtually any tissue, the only requirement for efficient targeting of potentially any antigen to dendritic cells is the packaging of the antigen with apoptotic cells or apoptotic cell material.

Accordingly, the scope of this invention includes an embodiment whereby the apoptotic cell delivery system is reconstituted in vitro using apoptotic cell fragments, or material thereof, including, but not limit to, proteins, phospholipids, carbohydrates and/or glycolipids, which enhance internalization and translocation of antigen to the appropriate antigen processing compartment in the dendritic cells. Thus, it is contemplated that liposomes comprising at least antigen and any combination of the aforementioned apoptotic cell fragments, or materials thereof, may enhance delivery of antigen to dendritic cells. Liposomes enhanced with apoptotic cell fragments, or materials thereof in accordance with this invention, can also be used for delivering antigen in vivo to dendritic cells.

As stated above, to prepare the liposomes it is desirable to include ligands for various receptors on the dendritic cells including various integrin receptors, CD36

◦ and heat shock proteins. It is also contemplated that various mutant forms or fragments containing binding domains of such proteins may also be used. If DC are pulsed with liposomes in vitro, between 0.1-1000 ng of antigen is preferred for priming between  $1 \times 10^5$  and 5 million DCs. Higher amounts of antigen in liposomes are used to deliver between about 10 ng to 10  $\mu$ g per immunization if DCs are to be pulsed in vivo.

In another embodiment, the apoptotic cell antigen delivery system can be used as a method for identifying and isolating poorly characterized antigens. For example, a population of tumor cells can be induced to undergo apoptosis, the apoptotic tumor cells can then be co-cultured with dendritic cells for a time sufficient to allow relevant immunogenic peptides to be processed and presented on the dendritic cell surface. The immunogenic peptides can then be eluted from the MHC and other presenting molecules of dendritic cell surface as disclosed in U.S. Patent 5,851,756 and purified using standard protein purification techniques known in the art including, but not limited to, HPLC and mass spectrophotometry.

#### 25 Activation of Dendritic Cells and CTLs

In yet another embodiment of this invention, the apoptotic cell-charged dendritic cells or the antigen-specific T lymphocytes generated by methods described herein may be used for either a prophylactic or therapeutic purpose. For activating T cells in an individual between about  $2 \times 10^5$  and  $2 \times 10^9$  more preferably between 1 million and 10 million apoptotic

- 37 -

cell-activated mature dendritic cells should be administered to an individual. The dendritic cells should be administered in a physiologically compatible carrier which is nontoxic to the cells and the individual. Such a carrier may be the growth medium described above, or any suitable buffering medium such as phosphate buffered saline (PBS). The mature dendritic cells prepared according to this invention are particularly potent at activating T cells. For example, using prior methods of dendritic cells the ratio of dendritic cells to T cells necessary for strong T cell activation is about 1 dendritic cell to 30 T cells whereas the ratio according to this invention is about 1 T cell to 1000 dendritic cells. Thus, fewer dendritic cells are required. For activating T cells in vitro the ratio of dendritic cells to T cells is between 1:10 and 1:1000. More preferably, between 1:30 and 1:150. Between approximately  $10^6$  and  $10^9$  or more activated T cells are administered back to the individual to produce a response against the antigen.

Dendritic cells may be administered to an individual using standard methods including intravenous, intraperitoneal, subcutaneously, intradermally or intramuscularly. The homing ability of the dendritic cells facilitates their ability to find T cells and cause their activation.

By adapting the system described herein, dendritic cells could also be used for generating large numbers of CD8<sup>+</sup> CTL, for adoptive transfer to immunosuppressed individuals who are unable to mount normal immune responses. Immunotherapy with CD8<sup>+</sup> CTL has

- 38 -

- been shown to amplify the immune response. Bone marrow transplant recipients given CMV specific CTL by adoptive transfer, do not develop disease or viremia (4). These novel approaches for vaccine design and prophylaxis should be applicable to several situations where CD8<sup>+</sup> CTLs are believed to play a therapeutic role e.g. HIV infection (1-3), malaria (5) and malignancies such as melanoma (8-9).

Examples of diseases that may be treated by the methods disclosed herein include, but are not limited to bacterial infections, protozoan, such as malaria, listeriosis, microbial infections, viral infections such as HIV or influenza, cancers or malignancies such as melanoma, autoimmune diseases such as psoriasis and ankylosing spondylitis.

By adapting the system described herein, dendritic cells could also be used for inducing tolerance. Dendritic cells expressing fas-L for example can kill fas expressing activated T cells (23). Thus, it may be possible to deliver fas-L bearing dendritic cells that are pulsed with apoptotic cells or blebs or bodies containing autoantigens to delete autoreactive T cells in vivo; or alternatively, one can target dendritic cells that are specialized to induce tolerance rather than immunity, as proposed for the subset of dendritic cells known as "lymphoid dendritic cells" (see Steinman et al., Immunol. Rev. 156: 25-37, 1997).

#### Methods for Assessing Cytotoxic T Cell Activity

Frequently, in clinical disease it is difficult to detect killer cells because of inadequate presentation. This invention also provides methods for assessing the



- 39 -

cytotoxic activity of T lymphocytes, and in particular the ability of cytotoxic T lymphocytes to be induced by antigen presenting dendritic cells. According to this method, a sample comprising T lymphocytes to be assayed for cytotoxic activity is obtained. Preferably, the cells are obtained from an individual from whom it is desirable to assess their capacity to provoke a cytotoxic T lymphocyte response. The T lymphocytes are then exposed to antigen presenting dendritic cells which have been caused to present antigen. Preferably, the dendritic cells have been primed with apoptotic cells which express antigen. After an appropriate period of time, which may be determined by assessing the cytotoxic activity of a control population of T lymphocytes which are known to be capable of being induced to become cytotoxic cells, the T lymphocytes to be assessed are tested for cytotoxic activity in a standard cytotoxic assay. Such assays may include, but are not limited to, the chromium release assay described herein.

The method of assessing cytotoxic T lymphocyte activity is particularly useful for evaluating an individual's capacity to generate a cytotoxic response against cells expressing tumor or viral antigens. Accordingly, this method may be useful for evaluating an individual's ability to defend against cancers, for example melanoma, or viruses. In addition, this method is useful to detect autoreactive killer cells and could monitor not only the presence of killer cells, but their response to therapy.

All books, articles, or patents referenced

- herein are incorporated by reference in their entirety.

### Example 1

#### Use Of Apoptotic Cells To Deliver Antigen To Dendritic 5                      Cells and Induce Class I-Restricted CTLs

##### Materials & Methods

Generation of mononuclear subsets. Peripheral blood  
mononuclear cells [PBMCs] were isolated from blood by  
10                      sedimentation in Ficoll-Hypaque [Pharmacia Biotech]. T  
cell-enriched [ER<sup>+</sup>] and T cell-depleted [ER<sup>-</sup>] populations  
were prepared by resetting with neuraminidase treated-  
sheep red blood cells, as previously described (37). T  
15                      cells were purified from ER<sup>+</sup> cells by removal of  
monocytes, NK cells and MHC class II<sup>+</sup> cells (37).  
Monocytes were obtained from ER<sup>-</sup> cells by plastic  
adherence. Dendritic cells were prepared from ER<sup>-</sup> cells  
cultured for 7 days in the presence of GM-CSF and IL-4,  
20                      followed by 4 days in monocyte conditioned medium (42,43).

Induction and detection of apoptosis. Monocytes were  
infected with influenza virus in serum free RPMI. Initial  
25                      time course studies established that after 5 hours,  
monocytes began to express early markers for apoptosis and  
that by 10 - 12 hours, a majority of the cells had been  
induced to undergo apoptosis. Cell death or Apoptosis was  
assayed using the Early Apoptosis Detection Kit [Kayima  
30                      Biomedical]. Briefly, cells are stained with Annexin V-  
FITC [Ann-V] and Propidium Iodide [PI]. Early apoptosis  
is defined by Ann V<sup>+</sup>/PI<sup>-</sup> staining as determined by

- 41 -

- FACScan® [Becton Dickinson]. 293 cells were triggered to undergo apoptosis using a 60UVB lamp [Derma Control, Inc.], calibrated to provide 2mJ/cm<sup>2</sup>/sec at a distance of 8 cm for 10 mins.

5     *Co-culture of DCs with Apoptotic Cells.* Monocytes from HLA-A2.1<sup>-</sup> individuals were infected with influenza virus. Live influenza virus [Spafas, Inc.] was added at a final concentration of 250 HAU/ml [MOI of 0.5] and incubated for 10     1 hour at 37°C (37). Heat-inactivated virus was prepared by incubating virus for 30 minutes at 56°C (39). Cells were washed with serum-containing medium and added to 24 well plates at varying cell doses. After 1 hour, contaminating non-adherent cells were removed and fresh 15     medium was added. Following a 10 hour incubation at 37°C, 3.3 x 10<sup>3</sup> uninfected DCs and 1 x 10<sup>6</sup> T cells were added to the wells.

20     *Assay for Virus-Specific CTLs.* After 7 days of culture, T cells were assayed for cytolytic activity using conventional Na<sup>51</sup>CrO<sub>4</sub> release assay (37). The targets were either influenza-infected syngeneic monocytes or T2 cells [a TAP<sup>-/-</sup>, HLA-A2.1<sup>+</sup>, class II<sup>-</sup> cell line] pulsed for 1 25     hour with 1 uM of the immunodominant influenza matrix peptide, GILGFVFTL (59,60). Specific lysis was determined by subtracting the percent cytotoxicity of uninfected monocytes or unpulsed T2 cells. Additionally, syngeneic 30     DCs were used as targets where noted. In such cases, direct percent cytotoxicity is reported.

*Reagents.* The Z-VAD-CHO [Kayima Biomedical] was added to

- 42 -

- monocytes for 1 hour prior to infection and subsequently washed out. DCs were cultured for 1 hour in Brefeldin A (BFA) [Sigma] or  $\text{NH}_4\text{Cl}$  [Sigma] and then maintained in these inhibitors for the course of the assay.

5

### RESULTS

Influenza A virus establishes a nontoxic infection in human DCs (37,38, 2016-4008). Once infected, these DCs are capable of eliciting virus-specific recall CTL responses within 7 days. The CTLs generated are class I- restricted and kill virus-infected monocytes and peptide pulsed target cells (37,39). Compared with DCs, influenza infected monocytes are poor stimulators of CTL responses (37) and undergo apoptosis (40,41). We have exploited these observations to investigate the role of apoptosis in the generation of antigen which could be acquired by uninfected DCs.

DCs were prepared from peripheral blood precursors of HLA-A2.1<sup>+</sup> individuals (42,43). Uninfected DCs and syngeneic T cells were co-cultured with influenza-infected syngeneic [Fig 1a] or allogeneic [Fig 1b] monocytes for 7 days. Influenza-specific CTLs were generated in these co-cultures, suggesting that the DCs acquired antigen from the monocytes. The DCs and not the infected monocytes functioned as the APC, since the latter failed to stimulate CTLs in the absence of DCs, even at a stimulator: responder ratio of 1:2 [Fig 1a, dashed lines]. The CTL responses generated in these co-cultures were as potent as those induced by influenza-infected DCs. In some experiments, as few as  $5 \times 10^3$  infected monocytes were

35

- 43 -

- sufficient to charge uninfected DCs for the induction of robust CTLs [Fig 1b]. Co-culturing influenza-infected HeLa cells with uninfected DCs also induced potent influenza-specific CTLs [data not shown]. The CTLs generated were capable of lysing influenza-infected syngeneic macrophage targets [Fig 1a] as well as matrix peptide-pulsed HLA-A2.1<sup>+</sup> T2 cells [Fig 1b].

To confirm that antigen is transferred to, and expressed directly by, DC MHC class I products, we co-cultured uninfected DCs and influenza-infected monocytes, and used the DCs as targets for CTLs [Fig 1c]. DCs co-cultured with infected monocytes were as efficient as virus-infected DCs at presenting antigen. These results suggest that influenza antigen from infected monocytes gained access to MHC class I of the DC, i.e. antigen from HLA mismatched monocytes were 'cross-priming' T cells via the DC.

Given the nature of the antigen, it was important to exclude live virus as the agent responsible for the transfer of antigen to DCs. Based on previous studies (14,20), influenza-infected monocytes produce only low levels of infectious virus before they undergo apoptosis. Infection of  $5 \times 10^4$  monocytes with an MOI of 2.0 would be expected to yield up to  $1 \times 10^3$  infectious virions after a 24 hour culture period. To prevent infection of DCs by monocyte produced virus, all experiments were done in human serum. The presence of blocking anti-hemagglutinin antibodies prevents influenza virions from binding to cell surface glycoconjugates. Indeed, the addition of influenza virus [highest dose,  $10^4$

◦ infectious virions] directly into cultures containing uninfected DCs and T cells did not generate a CTL response [data not shown]. To further exclude the possibility that monocytes were releasing virus during the 7 day co-culture, we tested for the presence of free virions using a standard hemagglutination assay with chicken RBC (45). Less than 1 HAU/ml [hemagglutination units per milliliter] was detected in the medium at 12 hr, 24 hr and 7 days of co-culture.

10 We also exclude the possibility that the CTL responses were due to free peptide being released by the dying monocytes, thereby charging class I molecules on DCs. Media from wells containing the infected monocytes were collected after an overnight culture and transferred to fresh wells containing T cells and uninfected DCs. Virus-specific CTLs were generated after a 7 day culture period [Fig 2a, 10 hr transfer]. However, this CTL activity was abrogated if the medium was passed through a filter [0.45 um pore size] prior to being added to T cell-DC cultures [Fig 2a, filter], suggesting that the antigenic material was neither live virus nor free peptide, as both would have passed through the filter. This was confirmed by sedimentation experiments [Fig 2b]. Media from wells containing the infected monocytes were removed and spun at 250 x g. The antigenic material could be localized in the pellet [Fig 2b, down arrow], but not in the supernatant fraction [Fig 2b, up arrow]. Notably, the pelleted material fully accounted for the CTL activity generated in direct transfer [Fig 2b, stars]. Hemagglutination activity could not be detected in the

- pelleted material, confirming that influenza virions were not trapped in this fraction. Furthermore, when the medium from infected monocyte cultures was pulsed onto T2 cells, they could not be targeted by influenza-specific CTLs [data not shown]. Collectively, these results are most consistent with the source of antigen being fragmented or intact apoptotic cells.

The role of apoptosis in the transfer of antigen to the uninfected DC was therefore assessed. We first show that influenza-infected monocytes undergo apoptosis as detected by annexin V binding, an early marker for programmed cell death [Fig 3a]. In contrast, heat-inactivated influenza virus, which reliably reduces viral replication, failed to induce apoptosis in monocytes [Fig 3a]. However, DCs that are infected with heat-inactivated virus remain capable of stimulating potent influenza-specific CTL responses. We employed this replication deficient virus to probe the requirement for apoptosis in cross-priming. When media from wells containing the heat-inactivated influenza-infected monocytes were collected after an overnight culture and transferred to fresh wells containing T cells and uninfected DCs, no influenza-specific CTLs were generated [Fig 3b, 10hr transfer, HI virus]. In contrast, DCs exposed to medium derived from live virus-infected monocytes, which contained apoptotic cells, did elicit a CTL response [Fig 3b, 10hr transfer, live virus]. However, if the heat-inactivated influenza-infected monocytes were allowed to undergo apoptosis spontaneously, as occurs during 7 days of culture (46), antigenic material was generated and virus-specific CTLs

- 46 -

- were induced [Fig 3b, co-culture, HI virus]. This data also argues against the possibility that live virus within the apoptotic cell is responsible for the transfer of antigenic material to the DCs.

5 To establish that apoptosis is the trigger for cross-priming, we first used Z-VAD-CHO, irreversible peptide inhibitor of caspase activity [Kamiya Biomedical Company]. It was possible to block apoptosis of influenza-infected monocytes [determined by TUNEL],  
10 without affecting the expression of viral proteins, [evaluated by staining with anti-nucleoprotein antibodies, data not shown]. Influenza-infected monocytes were cultured overnight in the presence of varying concentrations of Z-VAD. The medium from these wells were  
15 then added to fresh wells containing T cells and uninfected DCs. After 7 days, the responding T cells were measured for their influenza-specific cytolytic activity. At concentrations of Z-VAD which inhibited apoptosis of  
20 the infected monocytes, antigenic material was not transferred to the uninfected DCs and virus-specific CTLs were not generated [Fig 3c].

25 We next compared apoptotic death to necrotic death for the generation of antigenic material. Influenza-infected 293 cells were used for this experiment. Greater than 95% of the cells expressed influenza proteins after 10 hours, but unlike monocytes, apoptosis was not triggered. Apoptosis was induced in the  
30 293 cells by exposure to 60 mJ/cm<sup>2</sup> UVB irradiation (47), and necrosis was achieved by incubation in a hypotonic solution for 30 minutes at 37°C. Apoptotic or necrotic



cells were co-cultured with uninfected DCs and T cells for 7 days and responding T cells were tested as described above. Only apoptotic but not necrotic cells were capable of transferring antigen to the DCs, as determined by the generation of a potent influenza-specific CTL response [Fig 3d]. Similar findings were made when apoptotic versus necrotic influenza-infected monocytes were used as the source of antigen [data not shown].

The cellular requirements for generating CTLs via this pathway were also investigated. Given that lysis of T2 cells, an HLA-A2.1<sup>+</sup> cell line, was dependent on the matrix peptide, which is specific for HLA-A2.1, it was expected that the effectors were MHC class I-restricted [Fig 1b]. Indeed, when CD4<sup>+</sup> and CD8<sup>+</sup> subpopulations were purified at the end of the 7 day culture period, CTL activity was detected only in the CD8<sup>+</sup> fraction [data not shown].

We next examined whether co-cultures of uninfected DCs, influenza-infected monocytes and purified CD8<sup>+</sup> T cells could generate CTLs [Fig 4a]. Purified CD8<sup>+</sup> cells did not develop into potent CTLs in 3 separate experiments even when exposed to high doses of influenza-infected monocytes. The addition of CD4<sup>+</sup> T cells, but not human IL-2, restored the ability to generate influenza-specific CTLs. Thus, CD8<sup>+</sup> T cells require CD4<sup>+</sup> T cell help during the induction phase in this exogenous pathway, but once generated they are the sole effectors. Notably, DCs directly infected with influenza virus stimulate robust CTL responses from purified CD8<sup>+</sup> T cells, independent of CD4<sup>+</sup> T cell help or exogenous cytokines at

- stimulator: responder ratios as low as 1: 100 (37). The requirement for CD4<sup>+</sup> T cells in this exogenous pathway distinguishes it from the endogenous class I pathway. This observation is consistent with recent findings where CTL induction by cross-priming in vivo was shown to require CD4<sup>+</sup> T cell help, by direct action on the APC (24).

DCs and macrophages were compared as potential mediators of this exogenous pathway for class I MHC presentation. Uninfected HLA-A2.1+ DCs or macrophages, and syngeneic T cells were co-cultured with infected HLA-A2.1- monocytes. After 7 days, the responding T cells were measured for their influenza-specific cytolytic activity. DCs, but not macrophages, were capable of stimulating influenza-specific CTLs [Fig 4b]. In fact, as increasing doses of syngeneic uninfected macrophages were introduced into co-cultures containing uninfected DCs, T cells and infected allogeneic monocytes, the CTL activity was abrogated [Fig 4b]. Presumably, the macrophages act to sequester antigen from the DCs by efficiently engulfing the apoptotic cells.

Different pathways have been proposed for the presentation of exogenous antigen on MHC class I molecules. One possibility is that the antigens access the cytoplasm directly from the endosomal compartments and enter the 'classical' class I processing pathway (26,29). Alternatively, class I molecules associated with invariant chain may enter the endosomes (49). Finally, peptides generated in the endosomes may be regurgitated to the cell surface, charging class I molecules (34). We investigated

- 49 -

◦ if intracellular processing was required for DCs to present antigens from apoptotic cells. Uninfected DCs pulsed with influenza-infected allogeneic monocytes were used as targets for influenza specific CTLs [Table I]. A 3-9 hr co-culture of uninfected DCs and infected apoptotic monocytes was sufficient to charge DCs with antigen. The DCs were preincubated with 10 mM ammonium chloride, which neutralizes the endocytic compartment, or 6ug/ml Brefeldin A [BFA], an inhibitor of vesicular transport (50). Both ammonium chloride and BFA completely inhibited the DCs ability to present antigenic material on MHC class I. Lactacystin, an irreversible inhibitor of the 26S proteasome (51), only partially blocked antigen presentation by the uninfected DCs [unpublished data]. The data suggest that both classical and non-classical class I pathways are utilized for the presentation of exogenous antigen derived from apoptotic cells.

Since processing was required for presentation of monocyte derived antigen, immunofluorescence and electron microscopy were used to document that DCs phagocytosed apoptotic cells. By immunofluorescence, we observed phagocytosis of fragmented or intact cell bodies in 10-20% of the DCs [Fig 5a]. DCs were identified by the DC-restricted marker, p55, and apoptotic material was identified by intense DAPI staining of pyknotic nuclei. This was confirmed by electron and immuno-electron microscopy [Fig 5b,c]. Within the cytoplasm of 20-25% of the DCs, identified by expression of CD83 [Fig 5c, inset 1], we observed apoptotic cells with an apparently intact plasma membrane [inset 2]. We believe these images

- represent the method by which DCs acquire apoptotic cells. These results are consistent with a recent report where it was reported that DCs associate with apoptotic cells via the vitronectin receptor  $\alpha v \beta 3$ , but fail to associate with opsonized particles and necrotic cells (52).

5 Previous studies have shown that murine DCs have the capacity to present soluble antigens via an exogenous pathway, leading to the induction of MHC class I-restricted CTLs (32, 53-55). In addition, a single report  
10 reported that following intra-venous injection of allogeneic cells, rat interdigitating DCs within lymphnodes were found to contain whole cells and cell fragments (56). Using virus-infected monocytes, which  
15 themselves do not induce CTLs, we show that human DCs can acquire physiologically relevant antigens by phagocytosing apoptotic cells and then stimulating MHC class I-restricted CTLs.

## 20 Example 2

### Apoptotic transfected 293 cells serve as Antigenic Material for 'Cross-Priming' of CD8<sup>+</sup> T cells.

25 The methods and materials unless otherwise specified were the same as in Example 1.

The following methods were used to carry out the experiments shown in Figure 6. 293 cells, a human kidney  
30 epithelial cell line, were transfected with a construct encoding the matrix gene from Influenza A (filled triangles). After 2 days in culture,  $1 \times 10^4$  transfected 293 cells were added to fresh wells and were UV-B

- 51 -

- irradiated in order to induce apoptotic death. DCs and T cells were then added to these wells and after 7 days, responding T cells were assayed for influenza-specific cytolytic activity using matrix peptide pulsed T2 cells as targets.

5

### Results

The results demonstrate that a transfected tumor cell line can serve as a donor apoptotic cell, allowing for the transfer of antigen to the uninfected dendritic cell and the effective induction of antigen-specific CD8<sup>+</sup> CTLs. Controls included: mock transfected cells (open triangles), infected and uninfected 293 cells (filled and open circles, respectively), infected 293 cells without DCs (filled circles, dotted line), infected and uninfected DCs (filled and open diamonds, respectively).

15

### Example 3

20

#### CD8<sup>+</sup> T-Cells and not CD4<sup>+</sup> cells are responsible for Influenza-specific Cytotoxicity.

25

30

The following methods were used to carry out the experiments shown in Figure 7. Generation of CD8<sup>+</sup> CTLs requires CD4<sup>+</sup> T-cell help. Purification of CD8<sup>+</sup> and CD4<sup>+</sup> T cells after CTL induction, established that CD8<sup>+</sup> cells were responsible for the influenza-specific cytolytic activity. Influenza infected allogeneic monocytes were co-cultured with DCs and T-cells. After 7 days, subpopulations of T cells were purified and tested for cytolytic activity (37). Effector: Target ratio= 15:1.

35

- 52 -

### Results

Given that the lysis of T2 cells, an HLA-A2.1<sup>+</sup> cell line, was dependent on the matrix peptide, which is specific for HLA-A2.1, it was expected that the effectors were MHC class I-restricted (see Example 1). To confirm this, highly purified CD4<sup>+</sup> and CD8<sup>+</sup> subpopulations were isolated at the end of a 7 day culture period. As demonstrated in Fig.7, CTL activity was detected only in the CD8<sup>+</sup> fraction.

### Example 4

#### Immature DCs phagocytose Influenza Infected EL4 cells and Stimulate Influenza-specific CTLs

The following methods were used to carry out the experiments shown in Figure 8. Immature DCs were pulsed with various concentrations of UV irradiated influenza infected EL4 cells in the presence of monocyte conditioned media (a maturation signal for the DCs). After three days, the DCs were collected and cultured with 2 x 10<sup>5</sup> syngeneic T cells at responder : stimulator ratios of 30:1 and 100:1 in a 96-well microtiter plate. After 7 days in culture, responding T cells were tested in a standard 51Cr release assay using T2 target cells pulsed with the immunodominant epitope of influenza matrix protein. Controls included the use of UV irradiated uninfected EL4 cells as a source of apoptotic food. Influenza infected DCs and EL4s served as positive and negative controls, respectively. Effector : target ratio was approximately

- 25:1.

### Results

Immature DCs pulsed with apoptotic influenza infected EL4 cells in the context of monocyte conditioned media, were used to stimulate bulk T cells. The immature DCs efficiently engulf the murine tumor cell line and are able to cross-present influenza antigen derived from those apoptotic cells. Indeed, at a ratio of DCs:EL4s equal to 100:1, it was still possible to elicit potent T cells responses. This experiment also demonstrates the possibility of using xenotropic cells as a source of antigen bearing apoptotic cells for the delivery of antigenic material to the DCs.

### Example 5

Immature DCs but not Mature DCs and not Monocytes cross-present apoptotic material from apoptotic cells allowing for the targeting by influenza-specific CTLs

The following methods were used to carry out the experiments shown in Figures 9A and 9B.

Immature DCs but not Mature DCs or Monocytes cross-present antigenic material from apoptotic cells and become targets of antigen-specific CTLs. [Fig. 9A]. Various populations of HLA-A2.1+ professional antigen presenting cells (APCs) were co-cultured with HLA-A2.1-influenza infected monocytes. After 12 hrs, the APCs were loaded with <sup>51</sup>Cr and used as targets for influenza-specific CTLs. Mature DCs were sorted by

- 54 -

◦ FACSsort® (Becton Dickinson) by the DC-specific maturation marker CD83. Immature DCs were CD14- and sorted by FACSsort® as a CD83- population. Mature monocytes were generated by culturing an adherent mononuclear cell fraction in a teflon beaker adherent for nine days.

5 Immature monocytes are defined as cells cultured for two days post-plastic adherence. [Fig. 9B]. Controls included infected and uninfected APCs. HLA-A2.1- monocytes were also tested as targets to demonstrate the absence of lysis

10 when using a mis-matched target. Effector : Target Ratios = 45:1 and 15:1. Specific Lysis = (% killing of APC cross-presenting influenza infected monocytes) - (% killing of APC cross-presenting uninfected monocytes).

15 Background lysis ranged from 0 - 8%.

### Results

To better define the antigen presenting cell capable of cross-presentation of antigenic material

20 derived from the engulfment of apoptotic cells, an assay was established in which the APC is used as a target for antigen-specific CTLs in a standard chromium release assay. Various populations of HLA-A2.1+ professional APCs

25 were co-cultured with HLA-A2.1- influenza infected monocytes. After 12 hrs, the APCs were loaded with 51Cr and used as targets for an influenza-reactive CTL line. Specific lysis indicates that the APC had cross-presented

30 antigenic material derived from the apoptotic cell, leading to the presence of specific peptide-MHC class I complexes on its surface.

While mature DCs were capable of serving as



- 55 -

° targets when infected with influenza, they were unable to engulf apoptotic cells presumably because the mechanisms of antigen uptake, phagocytosis in this case, had been down regulated. Immature DCs co-cultured with apoptotic allogeneic influenza-infected monocytes were capable of serving as targets. When cultured in the presence of conditioned media, a maturation signal for the DC, these cells upregulate costimulator molecules which apparently permit the DCs to serve as more efficient targets.

5

10 Notably, neither the mature or the immature macrophages cross-presented antigenic material derived from the apoptotic cells. Unlike the mature DC population (which also do not serve as effective targets in this assay), these APCs are capable of phagocytosing apoptotic cells,

15 however the engulfed material is most likely degraded and not cross-presented on MHC class I. When the various HLA-A2.1+ APC populations were infected with influenza, all served as effective targets demonstrating that the differences described above were not a function of MHC

20 class I down-regulation or an inability for presentation of antigen.

The HLA-A2.1- monocytes which were used as a source of apoptotic cells were also tested as targets for the influenza-specific CTLs in order to confirm that the observed lysis was not due to killing of the allogenic influenza-infected monocytes. This result suggests that in vivo, it is the immature DC which is responsible for the uptake of apoptotic cells. After maturation and migration to a T cell rich area of a primary or secondary lymph organ, the DCs could stimulate CD8+ class-I

25

30

- ° restricted CTLs. Also indicated by this result is that the preferable method for immunotherapy would be to first co-culture immature DCs with apoptotic cells (a source of exogenous antigenic material) along with a maturation signal (CM, TNF  $\alpha$ , IL1  $\beta$ , IFN  $-\alpha$ , or some combination of the aforementioned) prior to injection.

#### Example 6

- 10 Efficient presentation of phagocytosed cellular fragments on MHC class II products of dendritic cells.

#### *Materials & Methods*

- 15 Mice. Adult 6-8 week mice [BALB/C, C57BL/6, BALB/C x DBA2 F1, C57BL/6 x DBA/2 F1] of both sexes were purchased from Taconic Farms [NY] and Japan SLC [Hamamatsu, Japan].
- 20 Cells. DCs were generated from bone marrow progenitors by culture in rGM-CSF as described (86). The cultures were set up in 24 well plates [Costar, Cambridge MA; Nunc, Naperville IL] and used at d6 when the wells were covered with aggregates of immature DCs. By d7-8,
- 25 aggregates release mature DCs, about  $10^5$ /well (86). Immature but not mature DCs are phagocytic for several particulates (79). B blasts were induced with lipopolysaccharide [E.coli 0111:B4, Sigma Chemical, St. Louis MO, 10,  $\mu$ g/ml] for 3-4d, or with anti- $\mu$  [Jackson Immunoresearch Labs, West Grove PA; F[ab]'<sub>2</sub> goat anti-mouse IgM] and IL-4 [Gibco-BRL] for 2d. B cells were
- 30 spleen cells that were passed over Sephadex G10 columns

- 57 -

◦ and depleted of T cells with antibodies and complement [thy-1, TIB 99; CD4, L3T4; CD8, TIB 211; all from ATCC]. In some cases, necrosis was induced in the B cells either by freeze-thawing 3-4 times, or with anti-B220 antibody [monoclonal J11d] and rabbit complement. Human cells were plastic adherent, monocytes from peripheral blood mononuclear cells and EBV-transformed B cell lines. Apoptosis was induced by infection with influenza (95), or by exposure to LPS [10 ng/ml] or UV light.

Antibodies. The Y-Ae hybridoma was generously provided by Dr. C. Janeway, Yale University, New Haven CT and grown serum-free. The IgG2b antibody was purified on protein A sepharose, biotinylated, and used in the FACS along with PE-streptavidin to detect MHC class II - peptide complexes (75,76) with a mouse IgG2b anti-human TCR antibody as the non-reactive control [PharMingen, San Diego CA]. The cells were double labeled for FACS and for microscopy with FITC antibodies to CD8, CD11c, CD86, I-Ab [AF6-120.1], I-Ad [39-10-8], and I-E [14-4-4S] [PharMingen].

*Capture of cell-derived peptides in vitro.* Bone marrow DCs were generated in 24 well plates for 6 days in GM-CSF, gently washed to remove mature floating DCs, and then fed B blasts, human cells, or a peptide [residues 56-73 of I-E $\alpha$ ]. Before adding I-E $^+$  cells or peptide, the DCs were immature, since much of the MHC class II was in intracellular lysosomal compartments and CD86 was not expressed at the surface (84) After uptake of I-E, the DCs matured with high levels of surface MHC II and CD86.

*Antigen presentation assays.* The 20.6 T-T

- 58 -

° hybridoma recognizes the MHC II-peptide complex that is detected with Y-Ae mAb (81). Graded doses of APCs were added to  $2 \times 10^4$  hybridoma cells in flat bottomed microtest plates. At 24h, supernatants were assayed for IL2 using a growth assay for conA stimulated T blasts.

5                    Capture of cell-derived peptides *in vivo*.  $2 \times 10^6$  H-2d BALB/C DCs were injected in PBS into the footpads of C57BL/6 [H-2b] or as a negative control, CBA/J [H-2k] mice. After 2 days, the draining lymph nodes were  
10 removed, frozen in OCT embedding medium, sectioned, fixed in absolute acetone 5 min, and stained successively with biotin-Y-Ae, avidin alkaline phosphatase conjugates, B220 for B cells, and peroxidase labeled mouse anti-rat Ig. We  
15 then could visualize the position of blue Y-Ae<sup>+</sup> cells relative to B cells which are found in white pulp follicles and scattered through the red pulp. To identify the Y-Ae<sup>+</sup> cells, DCs were enriched from the nodes as  
20 described 25 and double labeled for biotin Y-Ae and PE streptavidin [or nonreactive biotin IgG2b mAb as control] and different FITC conjugates to CD8, B220, CD11c, I-Ab, I-Ad.

### 25                    Results

25                    The development of many immune responses requires that antigen presenting cells [APCs] present antigens that initially are expressed by other cells. This antigen transfer to APCs may often be essential,  
30 since most cell types lack the migratory and costimulatory properties required to initiate a T cell response. Examples of responses that can develop following antigen

35

- 59 -

- transfer, often termed cross-priming and cross-tolerance, include the rejection of malignant cells and transplants, including xenografts (64-70), and the maintenance of tolerance to self tissues (71-73). However, underlying mechanisms have been difficult to identify directly.
- 5 Prior experimental approaches have utilized hematopoietic chimeras. In the chimera, the T cells that become primed to transplanted or malignant tissue [or tolerized to self] recognize antigen presenting MHC products on bone
- 10 marrow-derived cells. It is possible that antigen transfer simply involves the release of peptides from donor [tumor, transplant, self tissue] to recipient APCs. We have shown in the previous examples how human dendritic
- 15 cells [DCs] present viral antigens from apoptotic infected cells to MHC class I restricted, cytolytic T lymphocytes (74). In this example, we have used an antibody to directly monitor the formation of specific MHC class II
- 20 peptide complexes when DCs [which are bone marrow-derived] are exposed to other noninfected cells. In vitro, we find that antigen transfer requires phagocytosis, takes place with both xenogeneic and transformed cells. In vivo, where antigen transfer can be visualized with the antibody
- 25 to MHC-peptide, DCs serve as a powerful donor and recipient of cellular peptides. We propose that the steady state migration of DCs in afferent lymph, followed by processing by resident DCs in the T cell areas of lymphoid tissues, continuously tolerizes the T cell
- 30 repertoire to self.

To demonstrate the capacity of DC to present peptides from other cells, we took advantage of the Y-Ae

- 60 -

• monoclonal antibody. Y-Ae sees an MHC class II-peptide complex that is formed when one MHC II product, I-Ab, presents a peptide from residues 56-73 of another MHC II product, I-E $\alpha$  (75,76). Actually, the repertoire of peptides presented on MHC products typically include other MHC-derived peptides (77,78). We cultured C57BL/6 DCs [I-E $\alpha$ <sup>-</sup>, I-Ab<sup>+</sup>] with BALB/C B cells [I-E $\alpha$ <sup>+</sup>, I-Ab<sup>-</sup>] and monitored the capacity of DCs to react with Y-Ae by cytofluorography. The DCs were from 6 day cultures of GM-CSF stimulated mouse bone marrow, since these are known to have phagocytic activity, in contrast to the mature nonphagocytic DCs that predominate by day 7-8 of these cultures (79). The B cells were activated 3-4 with LPS or with anti- $\alpha$  plus IL-4 to express high levels of MHC II (80). When returned to culture, 20-40 % of the B blasts undergo apoptosis spontaneously, so that it is unnecessary to induce apoptosis in these I-E rich cells, in contrast to human monocytes (below) where the need for apoptosis is shown for transfer of cell-associated antigens to DCs.

Fig. 10A illustrates data from >30 experiments. H-2b DCs were cultured for 20h without peptide, with 1  $\mu$ M I-E $\alpha$  peptide, or with 2X10<sup>6</sup> B blasts from H-2d [I-E $\alpha$ <sup>+</sup>] or H-2b [I-E $\alpha$ <sup>-</sup>] mice. Y-Ae labeling developed when peptide was added. The labeling was highest on DCs that had matured to express high levels of the CD86 costimulator [black arrows denote mature DCs in each panel]. A Y-Ae signal that was comparable to that seen with peptide also developed on most DCs when I-E<sup>+</sup> [BALB/C] B blasts, but not I-E<sup>-</sup> [C57BL/6] B blasts, were added [Fig. 10A]. No labeling occurred with a nonreactive monoclonal,

- 61 -

◦ isotype-matched to antibody Y-Ae [Fig. 10A, lower]. The Y-Ae<sup>+</sup> cells had markers of DCs [CD11c<sup>+</sup>, I-Ab<sup>+</sup>] but not donor B cells [I-Ad<sup>+</sup>, CD86 low] [Fig. 10B]. No Y-Ae signal was detected on B blasts alone, or if B blasts were added to H-2d DCs [not shown]. In kinetic studies, the Y-Ae signal appeared after 5 hr of DC-B cell coculture and reached a plateau at 15-25 hr [Fig. 10C]. The signal then remained stable for 3 days, the longest we followed the cultures. The development of a Y-Ae signal on DCs depended on the B cell dose, and 4 day B blasts gave much stronger signals than unstimulated B cells [Fig. 10D]. B blasts can have 10 fold higher levels of MHC II products than small B cells (80). LPS and anti- $\mu$  blasts gave similar signals [not shown], with a plateau at a ratio of 10 B blasts per DC [Fig. 10D].

The MHC II-peptide complexes that formed during antigen transfer from B blasts to DCs could be recognized by T cells, as shown with a hybridoma that responds to the I-Ab/E $\alpha$  peptide complex by secreting IL-2 (81). Following a 20 hour exposure to I-E $\alpha$  peptide or B blasts, the DCs were sorted as CD11c/CD86<sup>+</sup> cells, fixed in formaldehyde to block further processing, added in graded doses to the T-T hybridoma for 24 hrs, and then the medium collected for testing in an IL-2 bioassay [<sup>3</sup>H-TdR uptake, Fig. 10E]. DCs obtained from DC-B blast co-cultures were potent APCs for T cells, almost as potent as DCs pulsed with I-E $\alpha$  peptide and DCs expressing endogenous I-Ab complexes [I-Ab x I-E<sup>+</sup> F1 mice].

To rule out the possibility that B blasts were simply releasing peptide to the DCs, we showed that Y-Ae

◦ labeling did not develop if B blasts were separated from DCs by a Transwell filter [0.45 $\mu$  pores], or if B blasts were added to nonphagocytic DCs that had undergone maturation in the bone marrow culture [Fig. 11A]. To prove that cellular processing was involved, we tested if 5 NH<sub>4</sub>Cl, which neutralizes the acidity of the endocytic system, blocked Y-Ae epitope formation. 5 mM NH<sub>4</sub>Cl partially, and 20 mM totally blocked Y-Ae development [Fig. 11B]; the inhibition was reversible [see below].

10 Since the immune response to xenografts also involves processing of donor cells by host APCs (70), we tested human cells as the donor of peptides to DCs. This was feasible with the Y-Ae monoclonal, since human HLA-DR $\alpha$  15 chain [residues] has the identical sequence to mouse I-E $\alpha$  56-73 (82-83). The Y-Ae epitope developed when mouse DCs were cultured with either EBV-transformed, human B lymphoblastoid cell lines [Fig. 11D] or with human monocytes [Fig. 11C]. For monocytes, we showed that 20 apoptotic cells [induced by influenza infection or exposure to UVB light] were processed more effectively than necrotic, freeze-thawed cells and that living monocytes were not processed [Fig. 11C]. Comparable 25 experiments on the need for apoptosis were difficult with mouse B blasts, since many of the B blasts died spontaneously in culture.

To demonstrate that phagocytosis preceded the 30 formation of the Y-Ae epitope, B blasts were fed to DCs in 20 mM NH<sub>4</sub>Cl. After 20 h, DCs were FACS<sup>®</sup> separated from residual B blasts and recultured for 12 h without NH<sub>4</sub>Cl. NH<sub>4</sub>Cl completely blocked Y-Ae epitope development [Fig.



- 63 -

- 12A, top], even within saponin-permeabilized cells (not shown), but the Y-Ae reappeared after removal of  $\text{NH}_4\text{Cl}$  [Fig. 12A, bottom]. The block imposed by  $\text{NH}_4\text{Cl}$  seemed primarily at the level of I-E processing, rather than peptide loading, since addition of I-E $\alpha$  peptide for 20 h to  $\text{NH}_4\text{Cl}$  cultures led to strong Y-Ae signals comparable to nonblocked cultures [Fig. 12B].

To determine whether this mechanism could function in vivo, we injected different I-A<sup>b</sup>- I-E<sup>+</sup> cell types [mouse splenocytes, B blasts and DCs; human monocytes] into the footpads of CS7BL/6 [I-A<sup>b</sup> I-E<sup>-</sup>] mice and then examined draining lymph nodes 2 days later for Y-Ae<sup>+</sup> cells. The negative controls were H-2k C3H recipients. Only mature DCs, derived from mouse bone marrow cultures (24), were found to be efficient donors of I-E peptide to MHC II of host cells, with numerous Y-Ae<sup>+</sup> cells developing in the DC-rich, T cell areas [Fig. 13A]. The finding was pursued by FACS analyses in which we examined cells that were enriched from the lymph nodes as described (87) [Fig. 13B]. The Y-Ae epitope was abundant, but again only in the situation where I-E<sup>+</sup> DCs-from BALB/C or C3H/He mice were injected into I-Ab recipients [C57BL/6 but not C3H]. The Y-Ae<sup>+</sup> cells had the phenotype of recipient DCs, positive for I-Ab and CD11c and negative for I-Ad, B220, and CD8 [Fig. 13B]. Most of the host, I-Ab and CD11c<sup>+</sup> DCs formed Y-Ae [Fig. 13B]. Since it is known that mature DCs are short-lived in culture (26) but in vivo can home to lymphoid organs prior to dying [reviewed in 27], we tested if live DCs had to be injected to observe antigen transfer. In fact, if most of the DCs

- ° were induced to apoptose by exposure to UV light just prior to injection, only small amounts of Y-Ae were formed [Fig. 13B]. Therefore by injecting mature living DCs, one presumably maximizes the interaction of donor and recipient DCs, the latter termed interdigitating cells, in the T cell areas (90).

Many immune responses require that APCs present antigens from other cells (63-73). Most cells in the body do not migrate to the T cell areas of lymphoid tissues and lack costimulatory functions [like CD86], both properties being important for selecting and activating T cell-mediated responses. In contrast, DCs are a potent system for stimulating T cell immunity and tolerance, having the required migratory and stimulatory functions (91). This data, together with data on the presentation of apoptotic, virus-infected cells on MHC class I (74) outline a new function for DCs, the presentation of antigens from other cells.

The consequences of antigen transfer to DCs, i.e., immunity [cross-priming] vs. nonresponsiveness [cross tolerance], may be influenced by stimuli in the DC environment. When DCs capture antigens from dying cells at a site of foreign antigen deposition, e.g., when microbial agents infect and kill somatic cells, or when transplants undergo rejection by what is termed the indirect pathway, the DCs may be altered by an inflammatory stimulus to be immunogenic. On the other hand, unresponsiveness or cross tolerance may develop when DCs capture antigens chronically from the normal, noninflammatory, apoptotic turnover of cells in vivo.

- Cross tolerance of self-reactive T cells is observed, for example, when antigens from  $\beta$  cells of normal, noninflammed pancreatic islets are presented by APCs in draining lymph nodes (72,73).

5           Substantial numbers of DCs traffic  
constitutively in the afferent lymph to the T cell areas  
where they almost certainly die, because the numbers of  
DCs in lymphoid tissues are normally steady and DCs do not  
emerge into the efferent lymph. Prior thinking has  
10 emphasized the potential value of this migratory, short  
lived, patrolling DC population to pick up foreign  
antigens and then present these in the T cell areas. Our  
results suggest that migratory DCs are also being  
15 processed distributing their peptides to other DCs in  
lymphoid organs. In our experiments, it is unlikely that  
Y-Ae<sup>+</sup> cells were first formed in the periphery since B  
blasts, splenocytes, UV-treated DCs and human monocytes  
each did not lead to Y-Ae epitope formation in lymphoid  
20 organs. Instead, it appeared necessary for viable DCs to  
first migrate to the lymphoid organ, and then the vast  
majority of host, I-Ab, lymph node DCs captured I-E<sup>+</sup> donor  
DCs to form the Y-Ae MHC-peptide complexes. The recipient  
25 Y-Ae<sup>+</sup> cells in the T cell areas, sometimes termed  
"lymphoid DCs," may be long-lived and are thought to have  
a regulatory function (90,92). In the steady state, i.e.,  
in the absence of inflammatory signals, the continued  
processing of migratory DCs and any cellular antigens that  
30 they have acquired from the normal turnover of cells in  
tissues, could purge the T cell repertoire of self  
reactivity (72,73), a function that is also carried out on

- 66 -

- developing T cells by DCs in the thymus (93,94). As result, when foreign inflammatory stimuli are to be presented to the immune system by DCs, there is less chance that autoreactivity to self antigens develops, since the same DC system has inactivated self reactive cells beforehand.

#### Example 7

Immature dendritic cells phagocytose apoptotic cells via  $\alpha_v\beta_5$  and CD36, and cross-present antigens to CTLs

#### *Materials and Methods*

*Media.* RPMI 1640 supplemented with 20  $\mu$ g /ml of gentamicin [Gibco BRL], 10 mM HEPES [Cellgro] and either 1% human plasma, 5% pooled human serum [c-six diagnostics] or 5% single donor human serum was used for DC preparation, cell isolation and culture conditions (113,119).

*Preparation of Cells.* Peripheral blood mononuclear cells [PBMCs], DCs, macrophages and T cells were prepared as previously described (113,114,119). Briefly, peripheral blood was obtained from normal donors in heparinized syringes and PBMCs were isolated by sedimentation over Ficoll-Hypaque [Pharmacia Biotech]. T cell enriched and T cell depleted fractions were prepared by rosetting with neuraminidase-treated sheep red blood cells (119). Immature dendritic cells [DCs] were prepared from the T cell depleted fraction by culturing cells in the presence of granulocyte and macrophage colony-stimulating factor [GM-CSF] and interleukin 4 [IL-4] for 7

◦ days. 1000 U/ml of GM-CSF [Immunex Corp.] and 500-1000 U/ml of IL4 [Schering-Plough Corp.] were added to the cultures on days 0, 2 and 4. To generate mature DCs, the cultures were transferred to fresh wells on day 7 and monocyte conditioned media [MCM] was added for an additional 3-4 days (113,114). At day 7, >95% of the cells were CD14<sup>-</sup>, CD83<sup>-</sup>, HLA-DR<sup>lo</sup> DCs. On day 10-11, 80-100% of the cells were of the mature CD14<sup>-</sup>, CD83<sup>+</sup>, HLA-DR<sup>hi</sup> phenotype. FACSsort® was used to generate highly pure populations of immature and mature DCs, based on their CD83<sup>-</sup> and CD83<sup>+</sup> phenotype, respectively. Macrophages were isolated from T cell depleted fractions by plastic adherence for one hour. After 24 hrs., cells were removed from the plates and placed in Teflon beakers for 3-9 days. T cells were further purified from the T cell enriched fraction by removing contaminating monocytes, NK cells and B cells (119).

*Antibodies.* Antibodies to the following proteins were used: CD8-PE, CD14-PE, HLA-DR-PE, HLA-DR-biotin [Becton Dickinson], IgG2b [clone 6603001, Coulter], CD8 [CRL 8014, ATCC], CD83 [clone HB15a, Coulter], MHC I [W6/32, ATCC clone HB95], CD36 [clone FA6, obtained from the Vth international workshop on leukocyte differentiation antigens],  $\alpha_v$  [clone CLB-706, Chemicon International Inc.; clone 69.6.5, Coulter],  $\beta_1$  [clone 6S6, Chemicon International Inc.],  $\beta_3$  [clone SZ21, Coulter; clone RUU-PL 7F12, Becton Dickinson],  $\beta_5$  [clone B5-IVF2, Upstate biotechnology],  $\alpha_v\beta_3$  [clone 23C6, Pharmingen],  $\alpha_v\beta_5$  [clone P1F6, Chemicon International Inc.], CD71 [Dako], Mannose receptor [clone 3.2PB1, a gift

- from A. Lanzavecchia], Nucleoprotein [ATCC clone HB85].

Induction of apoptotic death. Monocytes were infected with influenza virus in serum free RPMI. These cells undergo viral induced apoptotic death within 6-8 hours. Cell death was confirmed using the Early Apoptosis Detection Kit [Kayima Biomedical] (102). As previously described, cells are stained with Annexin V-FITC [Ann V] and Propidium Iodide [PI]. Early apoptosis is defined by Ann V<sup>+</sup> / PI<sup>-</sup> staining as determined by FACScan<sup>®</sup> [Becton Dickinson]. To ensure that we were studying the uptake of early apoptotic cells, the kinetics of death were carefully worked out. 5-8 hours post-infection, monocytes first externalize PS on the outer leaflet of their cell membrane, as detected with Ann V. By 8-10 hours, these cells were TUNEL positive. It was not until 24-36 hours that the majority of the monocyte population included trypan blue into the cytoplasm, an indicator of secondary necrosis [unpublished data, (120,121)]. HeLa cells were triggered to undergo apoptosis using a 60UVB lamp [Derma Control Inc.], calibrated to provide 2 mJ / cm<sup>2</sup> / sec. The kinetics of cell death in these cells has been previously defined (99).

Phagocytosis of apoptotic cells. Monocytes or HeLa cells were dyed red using PKH26-GL [Sigma Biosciences], and induced to undergo apoptosis by influenza infection or UVB irradiation, respectively. After 6-8 hours, allowing time for the cells to undergo apoptosis, they were co-cultured with phagocytic cells that were dyed green using PKH67-GL [Sigma Biosciences], at a ratio of 1:1. Macrophages were used 3-6 days after

isolation from peripheral blood; immature DCs were used on day 6-7 of culture; and mature DCs were used on day 10-11. Where direct comparison of cells was needed, cells were prepared from the same donor on different days. In blocking experiments, the immature DCs were pre-incubated in the presence of 50 µg/ml of various monoclonal antibodies for 30 minutes prior to the establishment of co-cultures. After 45-120 minutes, FACScan® analysis was performed and double positive cells were enumerated.

*Phagocytosis of latex beads.* Immature DCs were preincubated at 37° C with monoclonal antibodies specific for  $\alpha_v$  and  $\alpha_v\beta_5$ .  $10^6$  cells were then cultured with  $5 \times 10^7$  red fluorescent microspheres [diameter 1µ, 2.5% solids, carboxylate modified latex; Sigma] for varying periods of time. Alternatively, the cells were maintained 4° C. At the end of the assay, cells were separated from unengulfed beads by density gradient centrifugation and analyzed by FACScan® analysis (122).

*Immunofluorescence.* Cells were adhered to Alcian Blue [Sigma] treated cover slips and fixed in 100% acetone. Cells were stained with anti-influenza nucleoprotein antibody [HB85, ATCC] and Texas red conjugated goat anti-mouse IgG [Jackson ImmunoResearch]. This was followed by staining with biotinylated anti-HLA-DR [Becton Dickinson] followed by FITC conjugated streptavidin [Jackson ImmunoResearch]. Cells were visualized using an Zeiss Axioplan2 microscope.

*Assay for cross-priming of apoptotic cells.* Various APC populations were prepared as described above from HLA-A2.1<sup>+</sup> donors. Mature DCs were further purified by

- 70 -

- ° labeling with the DC-restricted marker CD83, followed by cell sorting on the FACSsort® [Becton Dickinson]. Immature DCs were CD14<sup>-</sup> and sorted by FACSsort® as a CD83<sup>-</sup> population. Mature macrophages were generated by culturing an adherent mononuclear cell fraction in a Teflon beaker for 9 days. These APC populations were co-cultured with HLA-A2.1<sup>-</sup> influenza-infected monocytes. After 12 hr., the APCs were loaded with Na<sup>51</sup>CrO<sub>4</sub>, and used as targets for influenza-specific CTLs in a standard chromium release assay (102,119). Specific lysis indicates that the APC had cross-presented antigenic material derived from the apoptotic cell, leading to the formation of specific peptide-MHC class I complexes on its surface. Specific Lysis = [% killing of APC cross-presenting influenza infected monocytes] - [% killing of APC cross-presenting uninfected monocytes]. Background lysis ranged from 0 - 8%. Controls included influenza infected and uninfected mature DCs, immature DCs and macrophages. The HLA-A2.1<sup>-</sup> monocytes used as a source of apoptotic material were also tested as targets to demonstrate the absence of lysis when using a mis-matched target. For the control targets, specific Lysis = [% killing of influenza infected APC] - [% killing of uninfected APC]. Background lysis ranged from 0 - 5%. Maximal influenza specific killing was determined using T2 cells [a TAP<sup>-/-</sup>, HLA-A2.1<sup>+</sup>, class II<sup>-</sup> cell line] pulsed for 1 hr with 1 M of the immunodominant influenza matrix peptide, GILGFVFTL as targets (123). Responses varied from 25-60% as a function of the individual's prior exposure to influenza.

RT-PCR. RNA was purified from highly purified



- 71 -

sorted cell populations of immature and mature DCs as described above. Messenger RNA for  $\beta_3$ ,  $\beta_5$  and CD36 were identified using an one step RT-PCR reaction [Titan kit, Boehringer Mannheim]. The forward primer 5'-TGAGAAAGTGCCCCCTGCCC was used for both  $\beta_3$  and  $\beta_5$ . The reverse primers 5'-GTTGGCTGTGTCCCATTTTGCT and 5'-TTGTAGGATTTGTGAACTTG were used for  $\beta_3$  and  $\beta_5$  to obtain 438 bp and 509 bp products, respectively [primer sequences were generously provided by S. Silletti]. The forward primer 5'-GGGAATTCATATGAAATCATAAAAGCAACAAACAT and the reverse primer 5'-CGGAATTCTACATTTCACTTCCTCATTTTCTG for CD36 yielded a product of 392 bp (124). The RT reaction was carried out for 30 minutes at 56°C followed by 30 cycles of amplification. After 30 cycles of PCR the samples were visualized on an agarose gel.

### Results

*Immature DCs efficiently phagocytose apoptotic cells.* Based on previous observations that immature DCs are the cells responsible for capturing antigen (106), we predicted that apoptotic cells would be engulfed best by immature DCs. To test this hypothesis, we established a phagocytosis assay which allowed us to visually detect the uptake of apoptotic cells, and compare the phagocytic capacity of immature DCs, mature DCs and macrophages. Briefly, immature DCs were prepared by culturing a T-cell depleted fraction from peripheral blood in the presence of IL-4 and GM-CSF. Mature DCs were generated with the addition of monocyte conditioned medium [MCM] and these cells expressed the cell surface DC restricted maturation

marker CD83 (113,114,125). Macrophages were prepared by culturing a plastic adherent cell population in Teflon beakers for 3-9 days. As a source of apoptotic cells we used influenza infected monocytes (102); virus infection induces apoptotic death in these cells within 6-10 hours (102,120,121). Monocytes were first dyed red using PKH26-GL [Sigma Biosciences], and then infected with influenza virus as previously described (119). After 6-8 hours, the various APCs were dyed green using the fluorescent cell linker compound, PKH67-GL [Sigma Biosciences], and co-cultured with the apoptotic cells at a ratio of 1:1. After 2 hours at 37 °C, co-cultures of cells were analyzed by FACSscan® analysis, allowing for quantification of phagocytic uptake as double positive cells. 80% of the macrophages, 50% of the immature DCs, and less than 10% of the mature DCs engulfed the apoptotic monocytes after 2 hours of coculture [Fig. 14A]. The smear of double positive cells [PKH67 labeled APC that engulfed the PKH26 labeled apoptotic cells] indicates that both apoptotic bodies and whole apoptotic cells served as 'food' for the phagocytic cell [Fig. 14. panels iii., vi., ix.]. Note that as the forward scatter of the APCs increased and the setting of the FACS® shifted, the dying monocytes were excluded from the established region [Fig. 14. panels ii., v., viii.]. Maximal uptake by all APC populations was achieved within 2-4 hours and in part depended upon the source of apoptotic cell used [Fig. 14B and data not shown]. Given this kinetic data, we believe that macrophages and DCs engage and internalize dying cells while they still display features of early apoptotic

- death. This data also demonstrates that it is the immature DC which preferentially acquires apoptotic material as compared to the mature DC. The source of apoptotic cells was not critical, since we obtained similar results with UVB irradiated HeLa cells [Fig. 20 and data not shown].

5           To confirm that this FACS® assay was measuring phagocytosis, we carried out the assay at 4° C and in the presence of inhibitors of phagocytosis. Both low temperature [Fig. 15A], and cytochalasin D, an inhibitor of cytoskeletal function, blocked uptake [Fig. 15B].  
10           Phagocytosis by immature DCs also requires divalent cations as EDTA was inhibitory [Fig. 15C]. To visually confirm the uptake recorded by FACS®, we prepared cytopspins of the dyed co-cultures. The frequency of uptake  
15           correlated with that measured on FACS® [data not shown]. We also performed immunofluorescence on co-cultures of immature DCs, labeled with anti-HLA-DR [DR], and apoptotic influenza infected monocytes, labeled with anti-influenza  
20           nucleoprotein [NP] [Fig. 16]. In the top panel an apoptotic cell is seen just prior to being engulfed by a DC [large arrowhead]. Following phagocytosis, apoptotic cells were found in DR<sup>+</sup> vesicles [small arrows], but not  
25           in the cytoplasm.

          Only immature DCs cross-present antigen from the apoptotic cell on class I MHC. We next correlated the phagocytic capability of macrophages and DCs with their ability to cross-present antigenic material derived from  
30           apoptotic cells. The cells were prepared from HLA-A2.1<sup>+</sup> donors (113,114), co-cultured with HLA-A2.1<sup>-</sup> influenza-infected monocytes for 12 hr and then loaded with Na<sup>51</sup>CrO<sub>4</sub>

• for use as targets for influenza-specific CTLs (102,119). Specific lysis indicates that the APC cross-presented antigenic material derived from the apoptotic cell, by forming specific peptide-MHC class I complexes on its surface [Fig. 17A]. As a direct comparison with the endogenous pathway for class I MHC presentation, the same APC populations were infected with live influenza virus and used as targets [Fig. 17B].

While mature DCs were efficient targets when infected with influenza, they were unable to cross-present antigens, presumably because they had down regulated the ability to phagocytose the apoptotic monocytes. The immature DCs, however, did cross-present antigens from apoptotic cells. Furthermore, if the immature DCs were co-cultured with the apoptotic cells in the presence of MCM, a maturation stimulus, they were even better targets. This is possibly due to the up regulation of costimulator and adhesion molecules (108,126), or the increased stability of peptide-MHC I complexes. Given that maximal uptake of apoptotic cells by immature DCs occurs between 2-4 hours [Fig. 14B], we believe that cross-presentation of apoptotic material reflects of the phagocytosis and processing of early apoptotic cells rather than secondary necrotic cells [see Methods]. With respect to this issue, it is important to recognize that the influenza infected monocytes require 24 hours to undergo secondary necrosis [unpublished data, (120,121)].

Notably, macrophages which efficiently phagocytose apoptotic cells [Fig. 14A], did not cross-present antigens to CTLs [Fig 17B]. Presumably, the

- 75 -

engulfed material is degraded, not cross-presented on MHC I. This profound difference between the DC and macrophage populations is supported by our previous findings that macrophages do not cross-present antigens from apoptotic cells during the induction phase of a class I-restricted antigen-specific T cell response. In fact, when put into culture with DCs in a competition assay, they sequester the apoptotic material and abrogate the CTL response (102).

Immature DCs can be distinguished from macrophages by intracellular expression of CD83 and a unique profile of phagocytic receptors. We investigated the possibility that immature DCs might phagocytose apoptotic cells via pathways distinct from macrophages. To clearly distinguish these cells we characterized them phenotypically. Immature DCs are distinguished by the absence of both CD14, a macrophage restricted marker, and CD83, a maturation marker for DCs (125). We have extended the use of CD83, finding that immature DCs can be distinguished from both macrophages and mature DCs by their intracellular expression of CD83 [Fig. 18]. Macrophages do not express CD83 intracellularly nor extracellularly [Fig. 18], while mature DCs express CD83 both intracellularly and extracellularly [Fig 18].

These APC populations were examined for receptors involved in phagocytosing apoptotic material [Table 1]. These include:  $\alpha_v\beta_3$  and CD36 which act as co-receptors, for engulfment of apoptotic neutrophils and lymphocytes by macrophages (127,128); and CD14 which has been implicated in the uptake of apoptotic cells by

- ° macrophages (129). While studying the immature DC populations, we identified a discrepancy in the expression of the  $\alpha_v$  and  $\beta_3$  integrin chains and investigated the possibility that  $\alpha_v$  was dimerizing with an alternate  $\beta$  chain. Using antibodies which recognize combined epitopes of the  $\alpha_v\beta_3$  and the  $\alpha_v\beta_5$  heterodimers, we noted the selective expression of  $\alpha_v\beta_5$  on immature DCs [Fig. 19A]. As is true for most receptors involved in antigen uptake (106,107), the expression of CD36,  $\alpha_v\beta_5$  and mannose receptor on DCs is down regulated with maturation [Fig. 19B, Table 1].

Receptor Profile of various Antigen Presenting Cells

	Immature DC <sup>§</sup> Day 7	Mature DC <sup>#</sup> Day 11	Monocytes <sup>¥</sup> Day 0	Macrophages <sup>Δ</sup> Day 3	Macrophages <sup>Δ</sup> Day 9
CD8*	0 - 2 (3 ± 1) §	0 - 3 (4 ± 1)	0 - 1 (4 ± 1)	0 - 5 (3 ± 1)	1 - 2 (3 ± 1)
CD14*	1 - 10 (4 ± 1)	0 - 6 (4 ± 1)	83 - 97 (149 ± 90)	67 - 98 (61 ± 20)	49 - 90 (68 ± 48)
CD83†	8 - 43 (8 ± 4)	73 - 99 (114 ± 15)	0 - 1 (3 ± 1)	4 - 19 (4 ± 2)	2 - 14 (4 ± 2)
MHC I†	99 - 100 (311 ± 49)	96 - 100 (280 ± 69)	99 - 100 (99 ± 38)	97 - 99 (164 ± 24)	95 - 100 (116 ± 18)
HLA-DR*	88 - 100 (84 ± 35)	98 - 99 (188 ± 40)	94 - 99 (63 ± 9)	97 - 99 (173 ± 34)	5 - 89 (25 ± 27)
CD8†	3 - 9 (4 ± 1)	2 - 8 (3 ± 1)	0 - 2 (3 ± 1)	1 - 4 (3 ± 0)	1 - 5 (3 ± 1)
IgG2b†	3 - 7 (3 ± 1)	2 - 7 (3 ± 1)	0 - 2 (3 ± 0)	1 - 4 (3 ± 1)	1 - 5 (3 ± 1)
CD36†	75 - 99 (75 ± 31)	20 - 50 (9 ± 2)	89 - 99 (62 ± 18)	64 - 64 (59 ± 45)	9 - 55 (15 ± 16)
α <sub>v</sub> (CD51)†	45 - 76 (14 ± 3)	11 - 40 (9 ± 3)	2 - 12 (4 ± 1)	2 - 35 (6 ± 2)	18 - 75 (10 ± 5)
β <sub>1</sub> (CD29)†	99 - 100 (287 ± 57)	84 - 100 (112 ± 28)	95 - 100 (61 ± 33)	83 - 100 (72 ± 23)	68 - 99 (104 ± 29)
β <sub>3</sub> (CD61)†	14 - 34 (7 ± 2)	10 - 24 (6 ± 1)	76 - 91 (40 ± 16) ∞	15 - 85 (14 ± 9) ∞	19 - 92 (16 ± 9)
β <sub>5</sub> †	78 - 95 (30 ± 8)	32 - 57 (11 ± 2)	6 - 8 (5 ± 1)	8 - 15 (7 ± 2)	5 - 8 (3 ± 1)
α <sub>v</sub> β <sub>3</sub> (VnR)†	22 - 28 (7 ± 1)	14 - 30 (7 ± 2)	4 - 8 (4 ± 1)	7 - 27 (5 ± 2)	19 - 68 (10 ± 4)
α <sub>v</sub> β <sub>5</sub> †	81 - 90 (25 ± 5)	12 - 53 (9 ± 3)	1 - 14 (4 ± 1)	0 - 11 (3 ± 1)	6 - 15 (4 ± 1)
CD71†	75 - 99 (50 ± 29)	75 - 94 (61 ± 27)	3 - 7 (4 ± 0)	14 - 30 (7 ± 2)	58 - 81 (30 ± 7)
Mannose Receptor†	99 - 100 (272 ± 68)	38 - 80 (26 ± 11)	2 - 7 (4 ± 0)	24 - 63 (13 ± 8)	48 - 95 (34 ± 20)

\* PE-conjugated. † Unconjugated antibody. § Results are expressed as range of values, calculated as percentage of positive cells as compared to an isotype matched control antibody. Values in parentheses indicate the average of geometric mean fluorescence intensities of the various samples. ∞ The β<sub>3</sub> expression in the monocytes and day 3 macrophages does not match the α<sub>v</sub>β<sub>3</sub> expression due to contaminating platelets which stuck to the cells during isolation, as determined by staining with anti-CD41, data not shown. ¥ n = 4. Δ n = 5. # n = 6. \$ n = 7.

TABLE I

• To evaluate whether this down regulation could be observed on the level of mRNA expression, we performed RT-PCR using primers specific for  $\beta_3$ ,  $\beta_5$  and CD36 [Fig. 19C]. Immature DCs [lane 1] showed amplified DNA of the appropriate size for  $\beta_3$ ,  $\beta_5$  and CD36. In contrast, in mature DCs [lane 2] no  $\beta_5$ , and much less CD36 sequences were seen, while  $\beta_3$  sequences were comparable to that in immature cells. These data, while not quantitative, are consistent with the levels of protein expression observed by FACS® and suggests that phagocytic receptor expression in DCs may be regulated at a transcriptional level as mRNA expression of CD36 and  $\beta_5$  is down regulated during maturation.

15  $\alpha_v\beta_5$  and CD36 mediate phagocytosis of apoptotic cells in immature DCs. To demonstrate a direct role for  $\alpha_v\beta_5$  in the recognition of apoptotic cells by immature DCs, we performed the phagocytosis FACS® assay in the presence of antibodies specific for  $\alpha_v\beta_5$  [Fig. 20]. In addition to the blocking observed using the monoclonal to  $\alpha_v\beta_5$ , blocking was also detected when using monoclonal antibodies to  $\alpha_v$ ,  $\beta_5$  and CD36. Blocking was not observed when isotype matched monoclonals specific for  $\beta_1$ ,  $\beta_3$  or the transferrin receptor, CD71. Note, control antibodies were chosen which recognized surface receptors present on the immature DC [Fig. 20A, Table 1]. Monoclonal antibodies were tested in doses ranging from 10 - 80  $\mu\text{g/ml}$  [data not shown]. Maximal inhibition of phagocytosis of apoptotic cells was seen with mAbs specific for CD36,  $\alpha_v$ , and  $\beta_5$  at 50  $\mu\text{g/ml}$ . The inhibition of phagocytosis of apoptotic



cells by DCs was specific. We were unable to block the uptake red fluorescent latex beads, a control particle, by DCs in the presence of these monoclonal antibodies [Fig. 20B]. By histogram analysis, DCs phagocytose 1-6 particles per cell. MAb to  $\alpha_v\beta_5$  or  $\alpha_v$  did not alter the profile of these histogram plots [data not shown].

While some inhibition of phagocytosis was observed when using  $\alpha_v\beta_3$  this may in part be due to transdominance and/or the effect on the pool of free  $\alpha_v$  (130). For example, anti- $\alpha_v\beta_3$  antibodies suppress the intracellular signaling of the  $\alpha_5\beta_1$  integrin (131). Alternatively,  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  may be working cooperatively in the immature DCs. We therefore tested combinations of anti- $\alpha_v\beta_3$  and anti- $\alpha_v\beta_5$ , but did not observe an increase in the inhibition of phagocytosis. The low receptor density of  $\alpha_v\beta_3$  on DCs [average MFI of 7 +/- 2, Table 1] also makes it unlikely that this integrin heterodimer is involved in the engulfment of apoptotic cells by immature DCs.

Our data do not exclude a role for other receptors in the phagocytosis of apoptotic cells e.g. the putative phosphatidylserine receptor or the lectin receptor (100). In fact, other receptors are probably involved as blocking observed did not exceed 60%, even when combinations of all relevant mAbs were tested [data not shown]. CD14 is unlikely to be involved in the DC's engulfment of apoptotic cells, as DCs do not express this receptor [Table 1]. In macrophages, phagocytosis of apoptotic cells was inhibited by antibodies to  $\alpha_v$ ,  $\beta_3$ ,  $\alpha_v\beta_3$  and CD36 but not by antibodies to  $\beta_1$ ,  $\beta_5$  or  $\alpha_v\beta_5$  [data not

• shown]. This correlates with published data (101,128).

Cross-presentation of antigens to CTLs appears to have two critical features. It is mediated by DCs and apoptotic cells are the preferred source of antigen (102). The requisite stage of DC development for the acquisition  
5 of apoptotic cells is the immature phase. In fact, immature DCs, are 4-5 times more efficient than mature DCs in phagocytosis, a feature which also correlates with their ability to cross-present antigen. This exogenous  
10 pathway for class I MHC loading is highly effective: relatively few apoptotic cells [ratio of 1 per 10 DCs] are needed to charge the DCs as efficiently as the live replicating virus; exposure of 3-12 hours is sufficient  
15 for generating a peptide-MHC complex that is capable of activating CTLs; and it is relatively indiscriminate, as the cellular source can be allogeneic cells or xenogeneic cells (102,132). We believe our earlier studies with mature DCs are explained by the fact that our cell  
20 populations were asynchronous and that only by sorting these cells have the differences become apparent. Based on the findings presented here, we suggest that the peripheral tissue DC, exemplified by the immature DC, has an additional important role. It is responsible for  
25 phagocytosing cells within tissues which undergo apoptosis [e.g. secondary to viral infection; during normal cell turnover] and migrating to the draining lymph nodes where appropriate T cells are engaged. This pathway may be  
30 employed for stimulating or tolerizing CTLs and can account for the *in vivo* observations of cross-priming of tumor and viral antigens (104,133) and cross-tolerance of

- 81 -

- self proteins (105,134) in their requirement for a bone-marrow derived APC.

A sharp distinction was also demonstrated between immature DCs and macrophages in the handling of apoptotic material. While macrophages are more efficient at phagocytosing apoptotic cells than immature DCs, they fail to induce virus-specific CTLs (102). In fact, they cannot even generate effective levels of peptide / MHC I complexes. In a short-term assay, influenza-specific CTLs could not kill macrophages co-cultured with apoptotic cells. Therefore, macrophages degrade rather than cross-present the ingested apoptotic cells.

Additional evidence exists that macrophages process apoptotic cells differently from DCs, and prevent an immune response. Two groups have demonstrated that phagocytosis of apoptotic cells suppresses a subsequent inflammatory response to LPS stimulation. The macrophage's cytokine profile is skewed toward the synthesis of IL-10, IL-13 and TGF- $\beta$ , while the production of proinflammatory cytokines such as TNF- $\alpha$ , IL-1 $\beta$ , and IL-12 is down-modulated (136,137). Therefore, the resolution of inflammation is dependant on at least two pathways for removal of apoptotic cells: via macrophages which subvert and suppress proinflammatory responses; and via DCs, which stimulate T cell responses that clear pathogens responsible for the induction of the apoptotic death.

The  $\alpha_v\beta_5$  integrin receptor may be pivotal in the distinctive handling of apoptotic cells by immature DCs versus macrophages in that it's expression is restricted to the former. We suggest that the unique profile of

receptors expressed by immature DCs affects trafficking of phagocytosed apoptotic cells, and consequently facilitates cross-presentation. We have previously shown that  $\text{NH}_4\text{Cl}$  inhibits the DCs ability to process antigen derived from apoptotic cells, suggesting that processing in an acidic vesicle [e.g. CIIVs or MIICs] is required (102,132). Indeed, class I MHC may interact with processed antigens in such a compartment, as MHC I molecules have been described in association with invariant chain (138), and can recycle from the cell surface to class II vesicles (139). Additionally, there may be as yet undescribed routes whereby antigens within vesicles can enter the classical endogenous pathway as described recently for antigens derived from the ER (140).

$\alpha_v\beta_5$  and  $\alpha_v\beta_3$  have both been described to be important in angiogenesis, cell adhesion, migration and now in their ability to phagocytose apoptotic cells.  $\alpha_v\beta_3$  is critical in the phagocytosis of apoptotic cells in macrophages, where it acts in a cooperative way with CD36 and thrombospondin [TSP], collectively forming a 'molecular bridge' (142). Recently, it was reported that  $\alpha_v\beta_5$  but not  $\alpha_v\beta_3$  is critical for the engulfment of rod outer segments [ROS] by CD36<sup>+</sup> retinal pigment epithelial cells (143,144). This phagocytic system is also inhibited by anti-CD36 antibodies, suggesting that  $\alpha_v\beta_5$ , like  $\alpha_v\beta_3$ , might cooperate with CD36. Taken together with our observations, TSP, or possibly other soluble factors, may serve to bridge CD36,  $\alpha_v\beta_5$  and the apoptotic cell.

Although similarities in function exist,  $\alpha_v\beta_5$  can be distinguished from  $\alpha_v\beta_3$  in its use of various

- 83 -

ligands [e.g. VEGF vs. bFGF]; by the requirements for activation; and by the intracellular signaling pathways [e.g. indirect activation of PKC] (50). Also significant is the fact that the cytoplasmic domains of the two  $\beta$  chains are the portions which show the most considerable diversity (51). Thus, it is possible that the distinct use of the  $\alpha_v\beta_5$  vs.  $\alpha_v\beta_3$  integrin receptors might account for the specialized functions of DCs in the route by which apoptotic material is trafficked and presented. In other words, differential expression of  $\alpha_v\beta_5$  may be responsible for the DCs ability to cross-present antigenic material derived from apoptotic cells, whereas macrophages scavenge and degrade such material.

#### Example 8

##### Inhibition of integrin inhibited engulfment of apoptotic cells

We have shown in the previous Example that engulfment of apoptotic cells by immature DCs is a receptor mediated phagocytic event, as it is inhibited by EDTA, Cytochalasin D and low temperature (see Example 7) (147). Immature DCs express little  $\alpha_v\beta_3$ , instead they employ an alternate  $\alpha_v$  heterodimer, the  $\alpha_v\beta_5$  integrin receptor, for the efficient internalization of apoptotic cells. As is the case in the macrophage receptor complex,  $\alpha_v\beta_3$  / CD36, we believe that the  $\alpha_v\beta_5$  integrin receptor works in concert with CD36. The expression of this receptor pair is restricted to the immature DC and upon maturation, CD36 and  $\alpha_v\beta_5$  protein expression and their

- mRNA expression are both down regulated. This expression pattern fits what is known about DC biology—the immature cell is involved in antigen capture, while the mature stage is characterized by poor antigen acquisition, but instead is efficient at activating T cells.

5           In Example 7, we demonstrated that the uptake of apoptotic human monocytes, HeLa cells, and a murine macrophage cells line (RAW) by immature DCs are all inhibited by monoclonal antibodies specific for  $\alpha_v\beta_5$ ,  $\alpha_v$ ,  
10    $\beta_5$  and CD36. While we do not have direct evidence for the  $\alpha_v\beta_5$  / CD36 interaction, we know that addition of blocking antibodies for both receptors to DCs / apoptotic cells co-cultures does not result in increased inhibition. This  
15 suggested to us that these two receptors might be working in concert. Maximal inhibition achieved in the in vitro phagocytosis assay was never greater than 60%, suggesting that additional receptors are involved. Candidates  
20 include, the complement receptors CR3 and CR4, scavenger receptor A, a putative lectin receptor (possibly DEC-205), and a still undefined phosphatidylserine receptor (Reviewed in (149, 150)).

25           To better define the  $\alpha_v\beta_5$  / CD36 receptor complex on immature DCs, we have begun to search for a DC-restricted bridging molecule as it is unlikely that TSP-1 is the soluble factor involved in the  $\alpha_v\beta_5$  / CD36  
30 receptor complex. Notably, neither the addition of antibodies specific for TSP-1, nor the addition of purified TSP to DC / apoptotic cell co-cultures has an inhibitory effect (data not shown). In contrast, both are known to inhibit engagement with CD36 on macrophages, thus

- blocking the phagocytosis of apoptotic cells.  
Additionally, we have begun to investigate the role for IAP-1 in the activation of the  $\alpha_v\beta_5$  integrin.

Based on the data described herein regarding the characteristics of a specific molecular bridge between  
5 apoptotic cells and DCs we believe that Lactadherin, a major glycoprotein of the human milk fat globule membrane, (151-153) has several properties which suggest it may be a component of such a molecular bridge. Lactadherin has  
10 many of the properties required for acting as a molecular bridge between the immature DC and the apoptotic cell as milk fat globules (MFGs) and apoptotic cells share much in common. The membrane surrounding the MFG has the same orientation as the membrane of an apoptotic body / bleb  
15 (the outer leaflet of both is topologically identical to the plasma membrane); the external leaflet of the membrane encapsulating the droplet contains PS (likely due to a lack of flippase activity inherent to the MFG); and  
20 oligosaccharides comprised of fucose, galactose, N-acetylglucosamine and N-acetylgalactosamine (many of the same carbohydrate motifs found on the surface of dying cells) (152-154). The milk fat droplets are secreted from  
25 the lactating epithelial cells by a process of encapsulation in plasma membrane and is subsequently engulfed by the gut epithelium of the nursing child (155). Indeed, the characteristics which make Lactadherin  
30 successful at bridging the MFG with the gut epithelium are similar to those which are likely facilitating uptake of the apoptotic cells by the DC.

- Supporting data: A role for IAP-1.

Another proposed factor involved in the  $\alpha_v\beta_5$  / CD36 / Lactadherin complex is integrin associated protein-1 (IAP-1). IAP-1 is involved in the activation of the  $\alpha_v\beta_3$  / CD36 / TSP-1 complex on macrophages. IAP-1 is expressed on virtually all cells; it is present on immature DCs (data not shown); and likely interacts with other  $\alpha_v$  integrins as IAP-1 and  $\beta_5$  have been co-immunoprecipitated (195). To test the hypothesis that IAP-1 is responsible for the activation of the  $\alpha_v\beta_5$  / CD36 complex on immature DCs, blocking studies with monoclonal antibodies and pertussis toxin (PT) were performed—we tested the effect of these factors on the phagocytosis of apoptotic cells by immature DCs (see Example 7 for experimental details of phagocytosis assay).

Antibodies specific for IAP-1 (clone B6H12, Chemicon International Inc.) inhibited the phagocytosis of apoptotic cells, however the blocking observed was significantly less than that observed when using anti-ad antibodies (TABLE II). PT, the major virulence factor of *Bordetella pertussis* inhibits heterotrimeric  $G_i$ -proteins, also blocked the phagocytosis of apoptotic cells by immature DCs (TABLE II).

30

35



## Inhibitors of Phagocytosis \*

Added to Immature DC / Apoptotic cell coculture		Percent Inhibition (Std Dev.)
5	anti- CD8	0 (n/a)
	anti- $\alpha_v$	46.5 (0.5)
	anti- IAP-1	27.8 (3.5)
10	LB 40 $\mu$ M <sup>†</sup>	0 (n/a)
	LB 10 $\mu$ M	0 (n/a)
	LA 40 $\mu$ M	41.5 (1.5)
	LA 10 $\mu$ M	14 (8)
15	DMSO	0 (n/a)
	Herb 18 $\mu$ M <sup>§</sup>	66.5 (2.5)
	Herb 9 $\mu$ M	49 (2)
	Herb 1.8 $\mu$ M	6.5 (2.5)
	PT 200 $\mu$ g / ml <sup>∞</sup>	37.5 (4.5)
20	PT 50 $\mu$ g /ml	19 (10)
	CC 12 $\mu$ M <sup>~</sup>	4 (2)

\* Results are expressed as averages of 2-4 experiments with values indicating percent inhibition of phagocytosis of apoptotic cells as compared to respective control wells.

Controls were cocultures treated with anti- CD8, Lavendustin B (the inactive analog of Lavendustin A), or DMSO alone. Values in parenthesis indicate standard deviation.

<sup>†</sup> Lavendustin B (LB) and Lavendustin A (LA). LA is a cell-permeable inhibitor of protein tyrosine kinase activity but has little effect on protein kinase A or protein kinase C.

<sup>§</sup> Herbamycin A is a potent cell-permeable protein tyrosine kinase inhibitor and inhibits PDGF-induced phospholipase D activation ( $IC_{50} = 8 \mu$ g / ml) in a dose dependant manner.

<sup>∞</sup> Pertussis Toxin (PT) is an inhibitor of the heterotrimeric G-protein  $G_i$ .

<sup>~</sup> Chelethrine chloride (CC) is a cell-permeable inhibitor of protein kinase C ( $IC_{50} = 660$  nM).

° Taken together, our data suggests that  $\alpha_v\beta_5$  /  
CD36 / IAP-1 / Lactadherin receptor complex on immature  
DCs may be responsible for the efficient engulfment of  
apoptotic cells. Similar, but as yet unidentified factors  
could also serve to enhance the uptake of apoptotic cells  
5 (or fragments thereof) in our antigen delivery system.

#### Example 9

10 Consequences of cell death: exposure to necrotic  
but not apoptotic cells induces the maturation of  
immunostimulatory dendritic cells

#### Materials & Methods

Preparation of DCs. DCs were prepared as  
previously described (171-173). In brief, DCs were  
generated from T cell depleted PBMCs by culturing cells  
20 for 5-6 days in the presence of 1,000 U/ml granulocyte and  
macrophage colony-stimulating factor [GM-CSF, Immunex] and  
1,000 U/ml IL-4 [Schering-Plough Corp. Union, NJ]. RPMI  
1640 supplemented with 20  $\mu$ g/ml gentamicin, 10mM HEPES,  
25 [GIBCO] and 1% autologous plasma [heparinized] was used  
for cell culture. Cultures were supplemented with  
cytokines on days 2 and 4. On day 5-6 nonadherent immature  
DCs were collected and transferred to new six well plates.  
30 Mature DCs were generated by the addition of 50% v/v  
monocyte conditioned medium [MCM] on the day of transfer  
and harvested on days 8-9.

*Induction of Apoptosis and Necrosis.* 293 cells

◦ were dyed red with PKH 26 according to the manufacturer's protocol [Sigma Biosciences, St. Louis, USA]. UV-triggered apoptosis was induced using a 60UVB lamp [Derma Control Inc]. Cells were incubated for 6 hours following irradiation to allow the cells to undergo apoptosis.

5 Necrosis was achieved via repeated freezing and thawing. Immature DCs were dyed green with PKH 67 and then co-cultured with the apoptotic and necrotic cells for 3 hours at 4° or 37C°. Phagocytosis of apoptotic and necrotic

10 cells by immature DCs was defined by the percentage of double positive cells by FACS-Analysis as previously described (176). UV-triggered apoptosis was also induced using a 60mJ UVB lamp [Derma Control Inc.], calibrated to provide 2mJ/cm<sup>2</sup>/sec. Necrosis was achieved via repeated

15 freeze [-80C°] thawing [+37C°]. Necrotic cells were trypan blue positive and demonstrated a distorted or fragmented morphology.

*Cell lines.* The following cell lines were used:

20 Human cell lines consisted of EBV transformed B-lymphocyte cell lines [B-LCL cells], melanoma cells [SK29 cells], and kidney adenocarcinoma cells [293 cells] and were cultured in RPMI supplemented with 10% FCS. Mouse cell lines [B16

25 melanoma cells, L-cells, RAW cells, 3T3 cells] were grown in DMEM supplemented with 10% FCS.

*Monoclonal antibodies.* Monoclonal antibodies [mAbs] to the following antigens were used. CD83 [Immunotech, Coulter, Marseille, France ] and DC-LAMP

30 [generously provided by Dr. S. Lebecque, Schering Plough, Dardilly, France] are markers expressed primarily by mature DCs. CD86, HLA-DR, CD40, CD25, CD8, CD14 were

- 90 -

obtained from Becton-Dickinson [Mountainview, CA]. Isotype control mAbs included IgG1, IgG2a and IgG2b [Immunotech, Coulter, Marseille, France]. The secondary antibody was PE-conjugated Fab'<sub>2</sub> goat anti-mouse IgG heavy and light chain [Jackson, ImmunoResearch, Laboratories, Inc., Baltimore, USA]. The DC cell populations were phenotyped with the panel of mAbs listed above and analyzed on a FACSscan [Becton Dickinson, Mountain View, CA]. For intracellular staining cells were first fixed in 1% paraformaldehyde and then permeabilized with 0.5% saponin before incubation with the primary antibody.

*Co-culture of apoptotic or necrotic cells with immature DCs.* Apoptotic or necrotic cell lines were added at various ratios to day 5 or 6 immature DCs. After 48 hours of coculture the DCs were assayed for their T cell stimulatory capacity. For the superantigen dependent assay DCs were irradiated with 3000 rad prior to addition to syngeneic T cells in the presence of 0.1 ng/ml SEA. After 3 days, 4  $\mu$ ci/ml <sup>3</sup>H-thymidine was added for 16 hours. We observed background proliferation in 5 day co-cultures, of immature DCs and allogeneic T cells in the MLR, probably because of some DC maturation as a result of DC-T cell interactions. To avoid this, we fixed immature DCs after exposure to dying cells with 1% paraformaldehyde for 30 min on ice, washed extensively and added them in graded doses to allogeneic T cells. After 4 days, 4 uci/ml <sup>3</sup>H - thymidine was added for 16 hours. Immature and MCM matured DCs served as controls.

### Results

The immune system has to contend with two types

- 91 -

of cell death and their consequences. Necrosis, characterized by cell fragmentation resulting from severe and sudden injury, leads to the release of toxic intracellular contents which may induce inflammation (156). Apoptosis, an energy dependent and synchronized event, is considered non-inflammatory due to rapid scavenging by macrophages (156-158). Necrotic and apoptotic cells are also phagocytosed by dendritic cells, potent initiators of immunity, which induce T cell responses to antigens derived from these dying cells (159-161). Uptake is restricted to the immature stage of development when DCs are well equipped to acquire antigen but express low levels of the requisite MHC and costimulatory molecules needed for T cell stimulation (159). Upon receipt of a maturation signal, DCs downregulate antigen acquisition, express higher levels of costimulatory and MHC molecules and become stably differentiated to activate resting T cells. Maturation can be triggered by multiple stimuli including LPS, contact allergens, bacteria and viruses, cell products [monocyte conditioned medium-MCM, TNF $\alpha$ , IL-1 $\beta$ , PGE $_2$ , IFN-alpha (162-168)] and signalling molecules [CD 40L (169-170)]. Since it is the immature DC that captures antigen most efficiently, we investigated whether the uptake of dead or dying cells could initiate immunity by inducing DC maturation.

To generate immature DCs, we cultured freshly isolated blood monocytes in GM-CSF and IL-4 for 6 days. These cells are characterized by low levels of HLA and co-stimulatory molecules [CD40, CD86 (159)] and the DC

35

restricted, maturation associated markers CD83 and DC-LAMP  
[lysosomal associated membrane glycoprotein] (174). We  
first verified that immature DCs phagocytosed necrotic  
cells comparably to apoptotic cells (175). A FACS assay  
was employed where green PKH26-GL labeled DCs are visually  
assessed for their ability to take up red PKH67-GL labeled  
apoptotic or necrotic tumor cells [kidney adenocarcinoma,  
293 cells] at a ratio of 1:1 (176). Over 40% of immature  
DCs phagocytosed either apoptotic or necrotic cells within  
3 hours [Fig. 21 A,B,C]. Uptake was profoundly reduced  
when dead cells were co-cultured with DCs at 4°C,  
indicating that cells or cell fragments were being bound  
specifically. As expected, mature DCs displayed poor  
phagocytic activity for either apoptotic or necrotic cells  
[Fig. 21C]. As a control for the effects of phagocytosis,  
we added FITC-labeled latex beads to immature DCs which  
were then cultured for 48 hrs in the presence or absence  
of MCM, the latter to induce maturation. Uptake of latex  
beads by itself did not induce maturation, as monitored by  
surface CD83 expression, and furthermore did not inhibit  
maturation via MCM [Fig.21 D,E (177)].

We next monitored the effects of dying cells on  
the maturation of DCs. A panel of human cell lines was  
tested including a melanoma cell line [SK29 cells], kidney  
adenocarcinoma cells [293 cells] and EBV transformed B-  
lymphocyte cell lines [B-LCL] [Fig. 22 A,]. Again a 48hr  
co-culture was carried out at different ratios of dying  
cells to DCs [1:5 to 1:2], after which the DCs were  
collected, stained for markers indicative of maturation,  
and analyzed on a FACScan®. Exposure to necrotic cells,

◦ but not apoptotic cells, induced the expression of the maturation associated markers CD83 and DC-LAMP in a large percentage of DCs [Fig. 22 A,B,C] and upregulated both co-stimulatory [CD86] and HLA molecules [Fig. 22 D,E]. Furthermore, CD40 levels almost doubled following exposure to necrotic cells [Fig. 22]. The induction of maturation was irreversible as DCs did not revert to an immature phenotype in culture. Necrotic mouse cell lines, including L-cells, 3T3 cells and B16 melanoma cells, also induced the maturation of DCs. Interestingly, when we added an excess of apoptotic cells to DCs at ratios of 5:1 or 10:1 there was extensive DC death [data not shown]. In contrast, this dose of cells was recently reported to induce maturation of a murine DC line (178), but the apoptotic cells were cultured for 16 hrs prior to addition to DCs. It is possible that the apoptotic cells underwent secondary necrosis, and the latter induced maturation.

To define the nature of factors in necrotic cells that were responsible for inducing maturation, we collected supernatants from necrotic and apoptotic cell lines, filtered them through a 0.45 micron filter and added these to immature DC cultures. Supernatants from necrotic but not apoptotic cells induced maturation [Fig. 22 F]. Obvious candidates for maturation such as TNF- $\alpha$  and IL-1 $\beta$  were not detectable by ELISA in the supernatants [not shown].

Mature DCs are potent stimulators of T cells, the most straightforward assays being the induction of allogeneic T cell proliferation in the mixed leukocyte reaction [MLR] and superantigen dependent T cell

proliferation (179, 180). After a 48 hour exposure to dying cells or their respective supernatants, DCs were washed, and added in graded doses to 200,000 allogeneic or syngeneic T cells, in the latter case together with 0.1 ng/ml staphylococcus enterotoxin A [SEA]. Strong stimulation of allogeneic and superantigen stimulated syngeneic T cells was observed with DCs that had been matured with necrotic cells, their respective supernatants or with MCM [Fig.23 A,B]. In contrast, exposure to apoptotic cells did not induce MLR stimulatory activity or superantigen dependent syngeneic proliferation above the low background in the absence of MCM [Fig. 23 A,B]. The <sup>3</sup>H-thymidine uptake data was confirmed by analysis of T cell size on the FACS<sup>®</sup> scan. In response to mature DCs [matured with MCM or with exposure to necrotic cells], >30% of the CD3+ T cells in the MLR were blasts [high forward light scattering], whereas immature DCs [no MCM, or exposure to apoptotic cells] induced <5% blast transformation [not shown]. Importantly, when DCs were exposed to a mixture of apoptotic and necrotic cells, they induced similar increases in T cell stimulation as DCs cultured with necrotic cells or their supernatants [data not shown]. Furthermore DCs exposed in parallel to apoptotic cells and MCM heightened T cell responses to the same extent as DCs matured with MCM. These experiments indicated that ingestion of apoptotic cells did not inhibit DC maturation or function. This contrasts with recently published data showing that phagocytosis of apoptotic cells induces immunosuppressive and anti-inflammatory effects in macrophages [e.g. release of IL-10



- 95 -

- and PGE<sub>2</sub> after LPS stimulation] and that apoptotic cells themselves can be sources of factors [e.g. IL-10] that skew the immune response (182-183).

While a role for macrophages in the phagocytic clearance of both apoptotic and necrotic cells is well known, there is little information on how DCs respond to dying cells. We find striking differences in the handling of dying, transformed cell lines depending on the mechanism of cell death. Necrotic cells selectively induce maturation of DCs. We would predict that in vivo, uptake of necrotic tumor cells would lead to the initiation of T cell responses to antigens processed by the DCs. These responses are likely to be CD4+ rather than CD8+, as antigens derived from necrotic cells do not induce CTLs, at least in vitro (160). Phagocytosis of apoptotic cells by DCs failed to induce maturation, the consequences of which may be the induction of tolerance to self or tumor antigens (184-186). Phagocytosis of apoptotic cells, however, may lead to T cell immunity if followed by a maturation signal. We have shown that DCs phagocytose apoptotic cells and present antigens [e.g. viral and tumor antigens] from these sources to both CD4+ and CD8+ T cells. See, Examples 1-5. Given that phagocytosis of apoptotic cells does not mature DCs, signals provided by necrotic cells in the environment, such as cytokines [e.g. TNF- $\alpha$ , IL-1 $\beta$ , IFN- $\alpha$  released by virus infected cells], inflammatory products [e.g. LPS, bacterial cell walls] and CD4+ T cells [such as CD40-L /CD40 interactions (169, 170)] would be required to mature the DCs, thus allowing for the full activation of T cells. In fact in in vivo

- 96 -

- animal models of cross-priming and cross-tolerance, induction of CTLs requires CD4<sup>+</sup> help [(184, 187-189) and data in vitro not shown].

5

10

15

20

25

30

35

°

References

1. Koup, R.A., C.A. Pikora, K. Luzuriaga, D.B. Brettler, E.S. Day, G.P. Mazzara, and J.L. Sullivan, 1991  
5 *J. Exp. Med.* 174:1593-1600.

2. Carmichael, A, X. Jin, P. Sissons, and L. Borysiewicz, 1993, *J. Exp. Med.* 177:249-256.

3. Johnson, R.P., A. Trocha, T.M. Buchanan and B.D. Walker, 1992, *J. Exp. Med.* 175:961-971.

10 4. McHichael, A.J. and B.A. Askonas, 1978, *Eur. J. Immunol.*, 8:705-711.

5. Hill, A.V.S., J. Elvin, A.C. Willis, M. Aidoo, C.E.M. Allsopp, F.M. Gotch, X.M. Gao, M.,  
15 Takiguchi, B.M. Greenwood, A.R.M. Townsend, A.J. McHichael, and H.C. Whittle, 1992, *Nature* 360:434-439.

6. Riddell, S.R., K.S. Watanabe, J.M. Goodrich, C.R. Li, M.E. Agha, and P.D. Greenberg, 1992  
*Science* 257:238-241.

20 7. Khanna, R. S.R. Burrows, A. Neisig, J. Neefjes, D.J. Moss and S.L. Silins, 1997, *J. Virol.* 71(10):7429-35.

8. Van Der Brogen, P., C. Traverari, P. Chomez, C. Lurquin, E. De Plaen, B. Van Deneynde, A. Knuth, and T. Boon, 1991, *Science* 254:1643-1647.

9. Young, J.W. and R.M. Steinman, 1990, *J. Exp. Med.*, 171:1315-1332.

30 10. Steinman, R.M., 1991, *Ann. Rev. Immunol.*, 9:271-296.

11. Jondal, M., R. Schirmbeck, and J. Reiman, 1996, *Immunity*, 5:295-302.

- °                   12. Kuzu, H., Y, Kuzu, H. Zaghouani, and C.  
Bona, 1993, *Eur. J. Immunol.*, 23:1397-1400.
13. Aichele, P., H. Hengartner, R.M.  
Zinkernagel, and M. Schulz, 1990, *J. Exp. Med.*, 171:1815-  
1820.
- 5                   14. Gao, X-M., B. Zheng, F.Y. Liew, S. Brett,  
and J. Tite, 1991, *J. Immunol.*, 147:3268-3273.
15. Schulz, M., R.M. Zinkernagel, and H.  
Hengartner, 1991, *Proc. Natl. Acad. Sci. USA*, 88:991-993.
- 10                  16. Moore, M.W., F.R. Carbone, and M.J. Brevan,  
1988, *Cell*, 54:777-785.
17. Zhou, F. and L. Huang, 1994, *Immunomethods*,  
4:229-235.
- 15                  18. Nair, S., F. Zhou, R. Reddy, L. Huang, and  
B.T. Rouse, 1992, *J. Exp. Med.*, 175:609-612.
19. Rubartelli, A. A. Poggi, and M.F. Zocchi,  
1997, *Eur. J. Immunol.*, 27:1893-1900.
20. Cohen, G.M., Biochen, J. (1997) 326:1-16.
- 20                  21. Miller, D.K. 1997 *Sem. Immunol* 5:35-49.
22. Wyllie, A.H. 1997 *Eur. J. Cell. Biol.*  
73:189-197.
23. Suss, G., and K. Shortman 1996 *J. Exp. Med*  
183:1789-1796.
- 25                  24. Inaba, K., M. Pack, M. Inaba, H. Sakuta, F.  
Isdell, and R. M. Steinman. 1997 . *Exp. Med.* 5:665-672.
25. Hemmels, M.T., & Ploegh, H. *Annual Review*  
*of Biochemistry* 64, 463-491 (1995).
- 30                  26. Watts, C., *Annu. Rev. Immunol.* 15, 821-850  
(1997).
- 35

27. Jondal, M., Schirmbeck, R. & Reimann, J.  
Immun., 5, 295-302 (1996).
28. Bevan, M.J. *J. Exp. Med.*, 143, 1283-1288  
(1976).
29. Kovacsovics-Bankowski, M. & Rock, K.L.  
Science, 267, 243-246 (1995).
30. Huang, A.Y.C., Golumbeck, P., Ahmadzadah,  
M., Jaffee, E., Pardoll, D. & Levitsky, H. *Science* 264,  
961-965 (1994).
31. Suto, R. & Srivastava, P.K. *Science*, 269,  
1585-1588 (1995).
32. Norbury, C. C., Chambers, B.J., Prescott,  
A. R., Ljunggren, H.-G. & Watts, C. *Eur. J. Immunol.* 27,  
280-288 (1997).
33. Pfeifer, J. D., Wick, M.J. Roberts, R. L.  
Findlay, K., Normark, S. J. & Harding, C. V. *Nature* 361,  
359-362 (1993).
34. Reis e Sousa, C. & Germain, R. N., *J. Exp.*  
*Med.*, 182, 841-851 (1995).
35. Kurts, C., Heath, W. R., Carbone, F. R.,  
Allison, J. Miller, J. F. A. P. & Kosaka, H. *J. Exp. Med.*,  
184, 923-930 (1996).
36. Kurts, C., Kosaka, H., Carbone, F. R.,  
Miller, J.F.A.P. & Heath, W.R. *J. Exp. Med.*, 186, 239-245  
(1997).
37. Bhardwaj, N., Bender, A., Gonzalez, N.,  
Bui, L. K., Garrett, M. C. & Steinman, R. M. *J. Clin.*  
*Invest.* 94, 797-807 (1994).
38. Bender, A., Albert, M., Reddy, A., et al.,  
*Immunobiology, in press* (1997).

- ° 39. Bender, A., Bui, L. K., Feldman, M.A. V.,  
Larsson, M. & Bhardwaj, N. J. *Exp. Med.*, 182, 1663-1671  
(1995).
40. Fesq, H., Bacher, M., Nain, M. & Gensa, D.  
*Immunobiol.* 190, 175-182 (1994).
- 5 41. Hofmann, P., Sprenger, H., Kaufman, A., et  
al. *J. Leuk. Biol.*, 612, 408-414 (1997).
42. Bender, A., Sapp, M., Schuler, G.,  
Steinman, R. M. & Bhardwaj, N. J. *Immunol. Methods* 196,  
10 121-135 (1996).
43. Romani, N., Reider, D., Heuer, M., et al.  
*J. Immunol. Methods* 196, 137-151 (1996).
44. Bender, A., Amann, U., Jager, R.,  
15 Nain, M. & Gensa, D. *J. Immunol.* 151, 5416-5424  
(1993).
45. Hirst, G. K., *J. Exp. Med.*, 75, 49-64  
(1942).
46. Badley, A. D., Dockrell, D., Simpson, M.,  
20 et al., *J. Exp. Med.* 185, 55-64 (1997).
47. Casciola-Rosen, J., Anhalt, G. & Rosen, A.  
*J. Exp. Med.* 179, 1317-1330 (1994).
48. Bennett, S. R. M., Carbone, F. R.,  
25 Karamalis, F. Miller, J. J. A. P. & Heath, W. R. *J. Exp.*  
*Med.* 186, 65-70 (1997).
49. Sugita, M. & Brenner, M. B. *Journal of*  
*biological chemistry* 270, 1443-1448 (1995).
50. Yewdell, J. W. & Bennink, J. R. *Science*  
30 268, 726-731 (1995).

51. Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J. & Schreiber, S. L. *Science* 268, 726-731 (1995).
52. Rubartelli, A., Poggi, A. & Zocchi, M. R. *Eur. J. Immunol.* 27, 1893-1900 (1997).
53. Shen, Z., Reznikoff, G., Droanoff, G. & Rock, K. L. *J. Immunol.* 158, 2723-2730 (1997).
54. Paglia, P., Choidoni, C., Rodolfo, M. & Colombo, M. P. *J. Exp. Med.* 183, 317-322 (1996).
55. Bachmann, M. F., Lutz, M. B., Layton, G. T., et al. *Eur. J. Immunol.*, 26, 1-7 (1996).
56. Fossum, S. & Rolstad, B. *Eur. J. Immunol.* 16, 440-450 (1986).
57. Bevan, M. J. *Journal of Immunology* 118, 1370-1374 (1977).
58. Arnold, D., Faath, S., Rammensee, H.-G. & Schild, H. *J. Exp. Med.* 182, 885-889 (1995).
59. Gotch, F., McMichael, A. & Rothbard, J. J. *Exp. Med.*, 182, 885-889 (1995).
60. Gotch, F., Rothbard, J., Howland, K., Townsend, A. & McMichael, A. *Nature* 326, 881 (1987).
61. Thornberry, N.A., & et al. *Nature* 356, 768-774 (1992).
62. De Panfililis, G., Manara, G. C. & Ferrari, C. *Journal of Investigative Dermatology* 87, (1986).
63. Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D. & Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. *Science* 264, 961-965 (1994).

64. Auchincloss, H. ,Jr. & Sultan, H. Antigen processing and presentation in transplantation. *Curr.Opin.Immunol.* 8, 681-687 (1996).
65. Bevan, M. J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. *J. Exp. Med.* 143, 1283-1288 (1976).
66. Liu, Z., Colovai, A. I., Tugulea, S., et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. *J. Clin. Invest.* 98, 1150-1157 (1996).
67. Benichou, G., Takizawa, P. A., Olson, C. A., McMillan, M. & Sercarz, E. E. Donor major histocompatibility complex [MHC] peptides are presented by recipient MHC molecules during graft rejection. *J. Exp. Med.* 175, 305-308 (1992).
68. Fangmann, J., Dalchau, R. & Fabre, J. W. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. *J. Exp. Med.* 175, 1521-1529 (1992).
69. Liu, Z., Sun, Y. K., Xi, Y. P., Harris, P. & Suci-Foca, N. T cell recognition of self-human histocompatibility leukocyte antigens [HLA]-DR peptides in context of syngeneic HLA-DR molecules. *J. Exp. Med.* 175 1663-1668 (1992).
70. Moses, R. D., Pierson III, R. N., Winn, H. J. & Auchincloss Jr., H. Xenogeneic proliferation and lymphokine production are dependent on CD4+ helper T cells and self antigen-presenting cells in the mouse. *J. Exp. Med.* 172, 567-575 (1990).



- 71. Kurts, C., Heath, W. R., Carbone, F. R., Allison, J., Miller, J. F. A. P. & Kosaka, H. Constitutive class I-restricted exogenous presentation of self antigens in vivo. *J. Exp. Med.* 184, 923-930 (1996).
- 5 72. Kurts, C., Kosaka, H., Carbone, F. R., Miller, J. F. A. P. & Heath, W. R. Class I-restricted cross-presentation of exogenous self antigens leads to deletion of autoreactive CD8+ T cells. *J. Exp. Med.* 186, 239-245 (1997).
- 10 73. Forster, I. & Lieberam, I. Peripheral tolerance of CD4 T cells following local activation in adolescent mice. *Eur. J. Immunol.* 26, 3194-3202 (1996).
- 15 74. Albert, M. L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. *Nature In Press*, (1998).
75. Rudensky, A. Y., Rath, S., Preston-Hurlburt, P., Murphy, D. B. & Janeway Jr., C A. On the complexity of self. *Nature* 353, 660-662 (1991).
- 20 76. Murphy, D. B., Rath, S., Pizzo, E., et al. Monoclonal antibody detection of a major self peptide. *J. Immunol.* 148, 3483-3491 (1992).
- 25 77. Chicz, R. M., Urban, R. G., Lane, W. S., et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. *Nature* 358, 764-768 (1992).
- 30 78. Hunt, D. F., Michel, H., Dickinson, T. A., et al. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. *Science* 256, 1817-1820 (1992).

- 79. Inaba, K., Inaba, M., Naito, M. & Steinman, R. M. Dendritic cell progenitors phagocytose particulates, including *Bacillus Calmette-Guerin* organisms, and sensitize mice to mycobacterial antigens in vivo. *J. Exp. Med.* 178, 479-488 (1993).
- 5 80. Nussenzweig, M. C., Steinman, R. M., Unkeless, J. C., Witmer, M.-D., Gutchinov, B. & Cohn, Z. A. Studies of the cell surface of mouse dendritic cells and other leukocytes. *J. Exp. Med.* 154, 168-187 (1981).
- 10 81. Ignatowicz, L., Kappler, J. & Marrack, P. The repertoire of T cells shaped by a single MHC/peptide ligand. *Cell* 84, 521-529 (1996).
82. Larhammar, D., Gustafsson, K., Claesson, L., et al. Alpha chain of HLA-DR transplantation antigens is a member of the same protein superfamily as the immunoglobulins. *Cell* 30, 153-161 (1982).
- 15 83. Schamboeck, A., Korman, A. J., Kamb, A. & Strominger, J. L. Organization of the transcriptional unit of a human class II histocompatibility antigen: HLA-DR heavy chain. *Nucl. Acids Res.* 11, 8663-8675 (1983).
- 20 84. Pierre, P., Turley, S. J., Gatti, E., et al. Developmental regulation of MHC class II transport in mouse dendritic cells. *Nature* 388, 787-792 (1997).
- 25 85. Cella, M., Engering, A., Pinet, V., Pieters, J. & Lanzavecchia, A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. *Nature* 388, 782-787 (1997).
- 30 86. Inaba, K., Inaba, M., Romani, N., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with
- 35

- granulocyte/macrophage colony-stimulating factor. *J. Exp. Med.* 176, 1693-1702 (1992).
87. Inaba, K., Pack, M., Inaba, M., Sakuta, H., Isdell, F. & Steinman, R. M. High levels of a major histocompatibility complex II - self peptide complex on dendritic cells from lymph node. *J. Exp. Med.* 186, 665-672 (1997).
88. Wong, B. R., Josien, R., Lee, S. Y., et al. TRANCE (tumor necrosis- factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell specific survival factor. *J. Exp. Med.* 186, 2075-2080 (1997).
89. Steinman, R. M. The dendritic cell system and its role in immunogenicity. *Annu. Rev. Immunol.* 9, 271-296 (1991).
90. Steinman, R. M., Pack, M. & Inaba, K. Dendritic cells in the T cell areas of lymphoid organs. *Immunol. Rev.* 156, 25-37 (1997).
91. Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. *Nature* In Press, (1998).
92. Vremec, D., Zorbas, M., Scollay, R., et al. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. *J. Exp. Med.* 176, 47-58 (1992).
93. Matzinger, P. & Guerder, S. Does T-cell tolerance require a dedicated antigen-presenting cell? *Nature* 338, 74-76 (1989).

- 94. Zal, T., Volkmann, A. & Stockinger, B.  
Mechanisms of tolerance induction in major  
histocompatibility complex class II-restricted T cells  
specific for a blood-borne self-antigen. *J. Exp. Med.* 180,  
2089-2099 (1994).
- 5 95. Fesq, H., Bacher, M., Nain, M. & Gemsa, D. Programmed  
cell death (apoptosis) in human monocytes infected by  
influenza virus. *Immunobiol.* 190, 175-182 (1994).
- 10 96. Fadok, V.A., J.S. Savill, C. Haslett, D.L.  
Bratton, D.E. Doherty, P.A. Campbell, and P.M. Henson.  
1992. Different populations of macrophages use either the  
vitronectin receptor or the phosphatidylserine receptor to  
recognize and remove apoptotic cells. *J. Immunol.*  
149:4029-4035.
- 15 97. Wyllie, A.H. 1980. Glucocorticoid-induced  
thymocyte apoptosis is associated with endogenous  
endonuclease activation. *Nature* 284:555-556.
- 20 98. Godman, G.C., A.F. Miranda, A.D. Deitch,  
and S.W. Tanenbaum. 1975. Action of cytochalasin D on  
cells of established lines. Zeiosis and movement at the  
cell surface. *J Cell Biochem* 64:644-647.
- 25 99. Casciola-Rosen, L., G. Anhalt, and A.  
Rosen. 1994. Autoantigens targeted in systemic lupus  
erythematosus are clustered in two populations of surface  
structures on apoptotic keratinocytes. *J. Exp. Med.*  
179:1317-1330.
- 30 100. Savill, J. 1998. Phagocytic docking without  
shocking. *Nature* 392:442-443.

- 101. Savill, J. 1997. Recognition and phagocytosis of cells undergoing apoptosis. *Br. Med. Bull.* 53:491-508.
102. Albert, M.L., B. Sauter, N. and Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. *Nature* 392:86-89.
- 5 103. Bevan, M.J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. *J. Exp. Med.* 143:1283-1288.
- 10 104. Huang, A.Y.C., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. *Science* 264:961-965.
- 15 105. Kurts, C., W.R. Heath, F.R. Carbone, J. Allison, J.F.A.P. Miller, and H. Kosaka. 1996. Constitutive class I-restricted exogenous presentation of self antigens in vivo. *J. Exp. Med.* 184:923-930.
- 20 106. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. *Nature* 392:245-252.
107. Sallusto, F., and A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate antigen in the MHC class II compartment. Downregulation by cytokines and bacterial products. *J. Exp. Med.* 182:389-400.
- 25 108. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus
- 30
- 35

- interleukin 4 and downregulated by tumor necrosis factor  
*α*. *J. Exp. Med.* 179:1109-1118.
109. Pierre, P., S.J. Turley, E. Gatti, M. Hull,  
J. Meltzer, A. Mirza, K. Inaba, R.M. Steinman, and I.  
Mellman. 1997. Developmental regulation of MHC class II  
5 transport in mouse dendritic cells. *Nature* 388:787-792.
110. Inaba, K., M. Inaba, M. Naito, and R.M.  
Steinman. 1993. Dendritic cell progenitors phagocytose  
particulates, including *Bacillus Calmette-Guerin*  
10 organisms, and sensitize mice to mycobacterial antigens in  
vivo. *J. Exp. Med.* 178:479-488.
111. Reis e Sousa, C., P.D. Stahl, and J.M.  
Austyn. 1993. Phagocytosis of antigens by Langerhans cells  
15 in vitro. *J. Exp. Med.* 178:509-519.
112. Inaba, K., M. Witmer-Pack, M. Inaba, K.S..  
Hathcock, H. Sakuta, M. Azuma, H. Yagita, K. Okumura, P.S.  
Linsley, S. Ikehara, S. Muramatsu, R.J. Hodes, and R.M.  
Steinman. 1994. The tissue distribution of the B7-2  
20 costimulator in mice: abundant expression on dendritic  
cells in situ and during maturation in vitro. *J. Exp. Med.*  
180:1849-1860.
113. Bender, A., M. Sapp, G. Schuler, R.M.  
25 Steinman, and N. Bhardwaj. 1996. Improved methods for the  
generation of dendritic cells from nonproliferating  
progenitors in human blood. *J. Immunol. Methods* 196:121-  
135.
114. Romani, N., D. Reider, M. Heuer, S. Ebner,  
30 B. Eibl, D. Niederwieser, and G. Schuler. 1996. Generation  
of mature dendritic cells from human blood: An improved
- 35

- method with special regard to clinical applicability. *J. Immunol. Meth.* 196:137-151.
115. Sallusto, F., C. Nicolo, R. De Maria, S. Corinti, and R. Testi. 1996. Ceramide inhibits antigen uptake and presentation by dendritic cells. *J. Exp. Med.* 5 184:2411-2416.
116. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kooten, I. Durand, and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross- 10 linking. *J. Exp. Med.* 180:1263-1272.
117. Rieser, C., G. Bock, H. Klocker, G. Bartsch, and M. Thurnher. 1997. Prostaglandin E2 and tumor necrosis factor  $\alpha$  cooperate to activate human dendritic 15 cells: Synergistic activation of interleukin 12 production. *J. Exp. Med.* 186:1603-1608.
118. Hess, K.L., G.F. Babcock, D.S. Askew, and J.M. Cook-Mills. 1998. A novel flow cytometric method for quantifying phagocytosis of apoptotic cells. *Cytometry* 20 27:145-152.
119. Bhardwaj, N., A. Bender, N. Gonzalez, L.K. Bui, M.C. Garrett, and R.M. Steinman. 1994. Influenza virus-infected dendritic cells stimulate strong 25 proliferative and cytolytic responses from human CD8+ T cells. *J. Clin. Invest.* 94:797-807.
120. Fesq, H., M. Bacher, M. Nain, and D. Gerns. 1994. Programmed cell death (apoptosis) in human monocytes infected by influenza virus. *Immunobiol.* 190:175-182. 30
121. Hofmann, P., H. Sprenger, A. Kaufmann, A. Bender, C. Hasse, M. Nain, and D. Gerns. 1997. Susceptibility of mononuclear phagocytes to influenza A 35

- ° virus infection and possible role in the antiviral response. *J. Leuk. Biol.* 612:408-414.
122. Steinkamp, J.A., J.S. Wilson, G.C. Saunders, C.C. and Stewart. 1981. Phagocytosis: Flow Cytometric Quantitation with Fluorescent Microspheres. *Science* 215:64-66.
123. Gotch, F., J. Rothbard, K. Howland, A. Townsend, and A. McMichael. 1987. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. *Nature* 326:881
124. Silverstein, R.L., M. Baird, S. Lo, and L.M. Yesner. 1992. Sense and antisense cDNA transfection of CD36 in melanoma cells. Role of CD36 as a thrombospondin receptor. *J. Biological Chemistry* 267:16607-16612.
125. Zhou, L.-J., and T.F. Tedder. 1995. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. *J. Immunol.* 154:3821-3835.
126. De Togni, P., J. Goellner, N.H. Ruddle, P.R. Streeter, A. Fick, S. Mariathasan, S.C. Smith, R. Carlson, L.P. Shornick, J. Strauss-Schoenberger, J.H. Russell, R. Karr, and D.D. Chaplin. 1994. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. *Science* 264:703-707.
127. Savill, J.S., I. Dransfield, N. Hogg, C. and Haslett. 1990. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. *Nature* 343:170-173.



- 111 -

128. Ren, Y., R. L. Silverstein, J. Allen, and J. Savill. 1995. CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis. *J. Exp. Med.* 181:1857. (Abstract)
129. Devitt, A., O.D. Moffatt, C. Raykundalia, J.D. Capra, D.L. Simmons, and C.D. Gregory. 1998. Human CD14 mediates recognition and phagocytosis of apoptotic cells. *Nature* 392:505-509.
130. Diaz-Gonzalez, F., J. Forsyth, B. Steiner, and M.H. Ginsberg. 1996. Trans-dominant inhibition of integrin function. *Molecular Biology of the Cell* 7:1939-1951.
131. Blystone, S.D., I.L. Graham, F.P. Lindberg, and E.J. Brown. 1994. Integrin alpha v beta 3 differentially regulates adhesive and phagocytic function of the fibronectin receptor alpha 5 beta 1. *Journal of Cell Biology* 127:1129-1137.
132. Inaba, K., S. Turley, F. Yamaide, T. Iyoda, K. Mahnke, M. Inaba, M. Pack, M. Subklewe, B. Sauter, D. Sheff, M.L. Albert, N. Bhardwaj, I. Mellman, and R.M. Steinman. 1998. Efficient presentation of phagocytosed cellular fragments on the MHC class II products of dendritic cells. *Submitted*.
133. Carbone, F.R., M.W. Moore, J.M. Sheil, and M.J. Bevan. 1988. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. *J. Exp. Med.* 167:1767-1779.
134. Heath, W.R., C. Kurts, J.F.A.P. Miller, and F. Carbone. 1998. Cross-tolerance: a pathway for inducing

- tolerance to peripheral tissue antigens. *J. Exp. Med.* 187:1549-1553.

135. Inaba, K., M. Inaba, N. Romani, H. Aya, M. eguchi, S. Ikehara, S. Muramatsu, and R.M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse  
5 bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J. Exp. Med.* 176:1693-1702.

136. Voll, R.E., M. Herrmann, E.A. Roth, C. Stach, and J.R. Kalden. 1997. Immunosuppressive effects of  
10 apoptotic cells. *Nature* 390:350-351.

137. Fadok, V.A., D.L. Bratton, A. Konowal, P.W. Freed, J.Y. Westcott, and P.M. Henson. 1998. Macrophages  
15 that have ingested apoptosis cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF- $\beta$ , PGE2, and PAF. *J. Clin. Invest.* 101:890-898.

138. Sugita, M., and M.B. Brenner. 1995. Association of the invariant chain with major  
20 histocompatibility complex class I molecules directs trafficking to endocytic compartments. *Journal of Biological Chemistry* 270:1443-1448.

139. Jondal, M., R. Schirmbeck, and J. Reimann. 1996. MHC class-I restricted CTL responses to exogenous  
25 antigens. *Immunity* 5:295-302.

140. Snyder, H.L., I. Bacik, J.R. Bennink, G. Kearns, T.W. Behrens, T. Bachi, M. Orlowski, and J.W.  
30 Yewdell. 1997. Two novel routes of transporter associated with antigen processing [TAP]-independent major

- histocompatibility complex class I antigen processing.  
*J. Exp. Med.* 186:1087-1098.
141. Rubartelli, A., A. Poggi, and M.R. Zocchi.  
1997. The selective engulfment of apoptotic bodies by  
dendritic cells is mediated by the  $\alpha v \beta 3$  integrin and  
requires intracellular and extracellular calcium. *Eur. J.*  
5 *Immunol.* 27:1893-1900.
142. Savill, J., N. Hogg, Y. Ren, and C.  
Hasslett. 1992. Thrombospondin cooperates with CD36 and the  
vitronectin receptor in macrophage recognition of  
neutrophils undergoing apoptosis. *Journal of Clinical*  
10 *Investigation* 90:1513-1522.
143. Ryeom, S.W., J.R. Sparrow, and R.L.  
Silverstein. 1996. CD36 participates in the phagocytosis  
of rod outer segments by retinal pigment epithelium.  
15 *Journal of Cell Science* 109:387-395.
144. Finnemann, S.C., V.L. Bonilha, A.D.  
Marmorstein, and E. Rodriguez-Boulan. 1997. Phagocytosis  
of rod outer segments by retinal pigment epithelial cells  
requires  $\alpha v \beta 5$  integrin for binding but not for  
20 internalization. *PNAS* 94:12932-12937.
145. Friedlander, M., P.C. Brooks, R.W. Shaffer,  
C.M. Kincaid, J.A. Varner, and D.A. Cheresh. 1995.  
Definition of Two Antigenic Pathways by Distinct  $\alpha v$   
Integrins. *Science* 270:1500-1502.
146. McClean, J. W., D. J. Vestal, D. A.  
Cheresh, and S. C. Bodary. 1990. cDNA Sequence of the  
30 Human Integrin  $\beta_5$  Subunit. *Journal of Biological Chemistry*  
265: 17126-17131.

147. Albert, M.L. et al. Immature dendritic cells phagocytose apoptotic cells via  $\alpha_v\beta_5$  and CD36, and cross present antigens to cytotoxic T lymphocytes. *J. Exp. Med.* 188:1359-1368 (1998).
148. Albert, M.L. & Bhardwaj, N. Resurrecting the Dead: DCs cross-present antigen derived from apoptotic cells on MHC I. *The Immunologist* 6:194-199 (1998).
149. Platt, N., da Silva, R.P. & Gordon, S. Recognizing death: the phagocytosis of apoptotic cells. *Trends Cell Biol.* 8:365-372 (1998).
150. Saville, J. Recognition and phagocytosis of cells undergoing apoptosis. *Br. Med. Bull.* 53, 491-508.
151. Larocca, D. et al. A Mr. 46,000 human milk fat globule protein that is highly expressed in human breast tumors contains factor VIII-like domains. Concl. *Res* 51:4994-4998 (1991).
152. Taylor, M.R. et al. Lacloodherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGP)-dependent cell adhesion. *DNA Cell Biol.* 16:861-869 (1997).
153. Peterson, J.A. et al. Glycoproteins of the human milk fat globule in the protection of the breast-fed infant against infections. *Biol Neonate* 74:143-162 (1998).
154. Mather, I.H. et al. Membranes of mammary gland. XII. Loosely associated proteins and compositional heterogeneity of bovine milk fat globule membrane. *J. Dairy Sci.* 60:394-402 (1977).

155. Patton, S.& Keenan, T.W. The milk fat  
° globule membrane. *Biochim Biophys Acta* 415:273-309  
(1975).
156. HV Arregaard, J. et. al. Characterization  
of glycoprotein PAS-6/7 from membranes of bovine milk fat  
globules Eur. J. Biochem. 240:628-636 (1996).  
5
157. J. Savill, *Br. Med. Bull.* 53, 491 (1997).
158. J. J. Cohen, *Immunol. Today* 14, 126 (1993).
159. E. Duvall, A. H. Wyllie, *Immunol. Today* 7,  
115 (1986).
- 10 160. J. Banchereau, R. M. Steinman, *Nature* 392,  
245 (1998).
161. M. L. Albert, B. Sauter, N. Bhardwaj,  
*Nature* 392, 86 (1998).
- 15 162. K. Inaba, et al, *J. Exp. Med.* In Press,  
(1998).
163. S. E. Macatonia, S. C. Knight, A. J.  
Edwards, S. Griffiths, P. Fryer, *J. Exp. Med.* 166, 1654  
(1987).
- 20 164. G. G. MacPherson, C. D. Jenkins, M. J.  
Stein, C. Edwards, *J. Immunol.* 154, 1317 (1995).
165. T. De Smedt, et al, *J. Exp. Med.* 184, 1413  
(1996).
- 25 166. J. A. Roake, et al, *J. Exp. Med.* 181, 2237  
(1995).
167. M. Rescigno, et al, *PNAS* 95, 5229 (1998).
168. N. Bhardwaj, et al, *J. Clin. Invest.* 94,  
797 (1994).
- 30 169. A. Bender, et al, *Immunobiology* 198, 64  
(1997).

170. C. Caux, et al, *J. Exp. Med.* 180, 1263  
° (1994).
171. M. Cella, et al, *J. Exp. Med.* 184, 747  
(1996).
172. A. Bender, M. Sapp, G. Schuler, R. M.  
5 Steinman, N. Bhardwaj, *J. Immunol. Methods* 196, 121  
(1996).
173. M. Cella, F. Sallusto, A. Lanzavecchia,  
*Curr.Opin.Immunol.* 9, 10 (1997).
174. N. Romani, et al, *J. Immunol. Meth.* 196,  
10 137 (1996).
175. B. de Saint-Vis, et al, *Immun.* 9, 325  
(1998).
176. M. L. Albert, et al, *J. Exp. Med.* 188, 1359  
15 (1998).
177. K. L. Hess, G. F. Babcock, D. S. Askew,  
Cook-Mills J.M. *Cytometry* 27, 145 (1998).
178. J. A. Steinkamp, J. S. Wilson, G. C.  
Saunders, C. C. Stewart, *Science* 215, 64 (1981).
- 20 179. P. Rovere, et al, *J. Immunol.* 161, 4467  
(1998).
180. P. S. Freudenthal, R. M. Steinman, *Proc.*  
*Natl. Acad. Sci. USA* 87, 7698 (1990).
- 25 181. N. Bhardwaj, S. M. Friedman, B. C. Cole, A.  
J. Nisanian, *J. Exp. Med.* 175, 267 (1992).
182. R. E. Voll, M. Herrmann, E. A. Roth, C.  
Stach, J. R. Kalden, *Nature* 390, 350 (1997).
- 30 183. V. A. Fadok, et al, *J. Clin. Invest.* 101,  
890 (1998).

- 117 -

184. Y. Gao, J. M. Herndon, H. Zhang, T. S.  
Griffith, T. A. Ferguson, *J. Exp. Med.* 188, 887 (1998).
185. W. R. Heath, C. Kurts, J. F. A. P. Miller,  
F. Carbone, *J. Exp. Med.* 187, 1549 (1998).
186. C. Kurts, H. Kosaka, F. R. Carbone, J. F.  
A. P. Miller, W. R. Heath, *J. Exp. Med.* 186, 239 (1997).
187. C. Kurts, W. R. Heath, H. Kosaka, J. F. A.  
P. Miller, F. R. Carbone, *J. Exp. Med.* 188, 415 (1998).
188. J. P. Ridge, F. Di Rosa, P. Matzinger,  
*Nature* 393, 474 (1998).
189. S. P. Schoenberger, R. E. M. Toes, E. I. H.  
van der Voort, R. Offringa, C. J. M. Melief, *Nature* 393,  
480 (1998).
190. S. R. M. Bennett, et al, *Nature* 393, 478  
(1998).
191. C. A. Janeway, *Immunol. Today* 13, 11  
(1992).
192. Andersen, M.H. et al. Bovine PAS-6/7 binds  
 $\alpha_v\beta_5$  integrins and anionic phospholipids through two  
domains. *Biochemistry* 36:5441-5446 (1997).
193. Amigorena, S. Anti-tumor immunotherapy  
using dendritic-cell-derived exosomes [In Process  
Citation]. *Res Immunol.* 149:661-662 (1998).
194. Raposo, G. et al. B Lymphocytes secrete  
antigen-presenting vesicles. *J. Exp. Med* 183:1161-1172  
(1996).
195. Hughes, P.E. & Pfaff, M. Integrin affinity  
modulation. *Trends Cell Biol.* 8:359-364 (1998).

o WE CLAIM:

1. A method of delivering antigen to dendritic cells comprising:  
  
5                   contacting dendritic cells with apoptotic cells  
expressing an antigen wherein said contact is for a time  
sufficient to allow said antigen to be internalized by the  
dendritic cells, and wherein said apoptotic cells have  
been induced in vitro to become apoptotic.
- 10   2. The method according to claim 1 wherein the dendritic  
cells are human.
- 15   3. The method according to claim 1 wherein the apoptotic  
cells are selected from the group consisting of cells of a  
cell line, cells which have been transformed to express a  
foreign antigen, tumor cell line, xenogeneic cells, or  
tumor cells.
- 20   4. The method according to claim 3 wherein the apoptotic  
cells are selected from the group consisting of  
  
                  monocytes, 293 cells, L cells, Hela cells, B  
cells and EL4 cells.
- 25   5. The method according to claim 1 further comprising  
the step of inducing apoptosis of cells expressing said  
antigen to produce the apoptotic cells.
- 30   6. The method according to claim 5 wherein apoptosis is  
induced by infection with influenza virus.



- o 7. The method according to claim 5 wherein apoptosis is induced by irradiation with ultraviolet light, gamma radiation, steroids, serum deprivation, cytokines, or drugs.
- 5 8. The method according to claim 5 wherein apoptosis is induced by depriving antigen donor cells of nutrients in the cell culture medium.
9. The method according to claim 1 wherein dendritic  
10 cells are exposed to a preparation of apoptotic cell fragments, blebs, or bodies containing antigen.
10. The method according to claim 1 wherein said antigen is selected from a group consisting of tumor antigens,  
15 viral antigens, pathogens, microbial antigens, self antigens, and autoimmune antigens.
11. The method according to claim 10 wherein the antigen is selected from the group consisting of influenza virus,  
20 malaria, HIV, EBV, human papilloma virus, CMV, renal cell carcinoma antigens, melanoma antigens, breast cancer antigens, cancer antigens and myeloma antigens.
12. The method according to claim 10 wherein the antigen  
25 is a tumor antigen.
13. The method according to claim 1 wherein said dendritic cells are immature and phagocytic.
- 30 14. The method according to claim 1 wherein the cells to be induced to undergo apoptosis are first transformed with DNA encoding said antigen.

15. The method according to claim 1 wherein the ratio of  
° apoptotic cells to dendritic cells is about 1-10 apoptotic  
cells to about 100 dendritic cells.

16. The method according to claim 1 wherein the dendritic  
cells are contacted with the apoptotic cells in vivo.

5 17. The method according to claim 1 wherein the dendritic  
cells are contacted with the apoptotic cells in vitro.

18. The method according to claim 1 further comprising a  
10 maturation step following internatlization of said  
apoptotic cells by said dendritic cells wherein said  
dendritic cells are exposed to a maturation factor for a  
sufficient time to induce maturation of said dendritic  
cells.

15 19. The method according to claim 18 wherein the  
maturation step comprises contacting the immature dendritic  
cells with at least one maturation factor selected from  
20 group consisting of monocyte conditioned medium, TNF $\alpha$ , IL-  
1 $\beta$ , IL-6, PGE<sub>2</sub>, IFN $\alpha$ , CD40 ligand, and necrotic cells.

20. The method according to claim 19 wherein the  
maturation factor is selected from the group consisting of  
25 monocyte conditioned medium; IFN $\alpha$  and at least one other  
factor selected from the group consisting of IL-1 $\beta$ , IL-6  
and TNF $\alpha$ ; and necrotic cells.

30 21. The method according to claim 20 wherein the  
maturation factor is necrotic cells.

- 121 -

22. A method of generating antigen-specific cytotoxic T lymphocytes comprising:

providing a population of apoptotic cells expressing said antigen;

- contacting dendritic cells with said apoptotic cells for a time sufficient to allow said antigen to be internalized and processed by said dendritic cells; and

- contacting T lymphocyte precursors with said dendritic cells for a sufficient time to induce the T lymphocyte precursors to become activated antigen-specific cytotoxic T lymphocytes.

23. The method according to claim 22 wherein said dendritic cells are exposed to a preparation of apoptotic cell fragments containing antigen.

24. The method according to claim 22 further comprising administering said antigen-specific cytotoxic T lymphocytes to an individual afflicted with a disease.

25. The method according to claim 22 further comprising administering said apoptotic-cell primed dendritic cells to an individual afflicted with a disease for the purpose of activating antigen-specific T lymphocytes, including helper and cytotoxic T cells, in vivo.

26. An antigen presenting dendritic cell prepared according to the method of claim 1.

- 122 -

27. Cytotoxic T lymphocytes prepared according to the  
° method in claim 22.

28. A method of assessing cytotoxic T lymphocyte activity  
comprising:

- 5 a) providing antigen presenting dendritic  
cells prepared according to the method of claim 1;
- b) exposing the antigen presenting dendritic  
cells to a population of T lymphocytes to be assayed for  
their ability to exhibit killer cell activity; and
- 10 c) assaying the cytotoxic activity of the T  
lymphocytes exposed to said antigen presenting dendritic  
cells.

29. The method according to claim 28 wherein the antigen  
15 presented by the dendritic cells is a tumor antigen and  
the T lymphocytes are assayed for their cytotoxic activity  
against tumor cells.

30. The method according to claim 28 wherein the antigen  
20 presented by the dendritic cell is a viral antigen and the  
T lymphocytes are assayed for their activity against viral  
infected cells.

31. A method of delivering antigen to dendritic cells  
25 comprising:

- contacting dendritic cells with a material selected  
from the group consisting of a reconstituted apoptotic  
cell system, apoptotic cell fragments, and liposomes  
30 comprising at least one antigen and a material which  
enhances internalization and translocation of antigen to  
an antigen processing compartment of said dendritic cells.

- 123 -

32. The method according to claim 31 wherein the material  
° for enhancing internalization is a ligand for the  $\alpha_v\beta_5$   
integrin receptor.

33. The method according to claim 32 wherein the ligand  
5 for the  $\alpha_v\beta_5$  integrin receptor is lactadherin.

34. The method according to claim 32 wherein the material  
for enhancing internalization is thrombospondin.

35. An in vitro culture comprising immature dendritic  
10 cells in contact with an antigen donor selected from the  
group consisting of apoptotic cells, a reconstituted  
apoptotic cell system, apoptotic cell fragments, and  
liposomes comprising at least one antigen and a material  
15 which enhances internalization and translocation of  
antigen to an antigen processing compartment of said  
dendritic cells.

36. The in vitro culture according to claim 35 wherein  
20 the dendritic cells are in contact with apoptotic cells.

37. An in vitro culture of immature dendritic cells  
wherein said dendritic cells further comprise antigen  
obtained from apoptotic cells.

25 38. An in vitro culture of mature dendritic cells  
prepared according to the method of any one of claims 19-  
22.

30 39. A pharmaceutical composition comprising dendritic  
cells which present antigen internalized from an apoptotic  
donor cell and wherein said pharmaceutical compositions

- 124 -

further comprises a pharmaceutially acceptable carrier.

o

40. The pharmaceutical composition according to claim 39 wherein the dendritic cells are immature.

5

41. The pharmaceutical composition according to claim 39 wherein the dendritic cells are mature.

42. The pharmaceutical composition according to claim 41 wherein the internalized antigen is a tumor antigen.

10

43. A method of immunizing an individual against an antigen comprising administering to an individual an amount of dendritic cells sufficient to activate T cells, wherein said dendritic cells have been contacted with antigen present on a donor selected from the group consisting of apoptotic cells, a reconstituted apoptotic cell system, apoptotic cell fragments, and liposomes comprising a material which enhances internalization and translocation of antigen to an antigen processing compartment of said dendritic cells.

15

20

44. The method according to claim 43 wherein the dendritic cells administered to an individual are immature.

25

45. The method according to claim 43 wherein the dendritic cells are contacted with a maturation factor and caused to mature prior to their administration to the individual.

30

46. A method of activating CD4+ T cells comprising contacting a population of T lymphocytes with dendritic

35

- 125 -

cells which have been contacted with antigen present on  
° necrotic cells and wherein the dendritic cells express  
antigen on MHC class II receptors.

47. The method according to claim 46 wherein the tumor is  
a tumor antigen.

5

48. A method of activating CD4+ and CD8+ T cells against  
tumor cells comprising a tumor antigen, said method  
comprising contacting immature dendritic cells with  
apoptotic and necrotic cells which express said tumor  
10 antigen for a period of time sufficient for said dendritic  
cells to process said tumor antigen and present the tumor  
antigen on class I and II MHC receptors and for said  
dendritic cells to mature, and further contacting said  
15 antigen presenting dendritic cells with a population of T  
lymphocytes to cause activation of CD4+ and CD8+ T  
lymphocytes.

20

25

30

35

1/38




FIG. 1A




FIG. 1B




FIG. 1C



2/38




FIG. 2A




FIG. 2B

3/38




FIG. 3A




FIG. 3B

4/38




FIG. 3C




FIG. 3D

5/38




FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B



8/38




FIG. 6

9/38




FIG. 7




FIG. 8



10/38




FIG. 9A




FIG. 9B

11/38




FIG. 10A




FIG. 10B

12/38




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 12A






FIG. 12B

19/38




FIG. 12C




FIG. 13A




FIG. 13B




FIG. 13C

23/38




FIG. 14A

24/38





FIG. 14B










FIG. 16

27/38



Targets pulsed with influenza  
infected apoptotic cells

FIG. 17A



Targets infected with live  
influenza virus

FIG. 17B

28/38




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 19A




FIG. 19B





FIG. 19C

31/38



Immature DCs phagocytosing  
Apoptotic HeLa cells  
(% inhibition relative to untreated cells)

FIG. 20A




FIG. 20B

FIG. 21A




FIG. 21B

FIG. 21C

33/38




FIG. 21D




FIG. 21E



34/38




FIG. 22A

35/38




FIG. 22B




FIG. 22C

36/38




FIG. 22D




FIG. 22E

37/38




FIG. 22F

38/38




FIG. 23A




FIG. 23B

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 5/00, A61K 39/00, 35/14, G01N 33/50</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/42564</b> <b>(43) International Publication Date:</b> 26 August 1999 (26.08.99)
<b>(21) International Application Number:</b> PCT/US99/03763 <b>(22) International Filing Date:</b> 19 February 1999 (19.02.99)  <b>(30) Priority Data:</b> 60/075,356 20 February 1998 (20.02.98) US 60/077,095 6 March 1998 (06.03.98) US 60/101,749 24 September 1998 (24.09.98) US  <b>(71) Applicant:</b> THE ROCKEFELLER UNIVERSITY [US/US]; 1230 York Avenue, New York, NY 10021-6399 (US).  <b>(72) Inventors:</b> ALBERT, Matthew, L.; 500 East 63rd Street, New York, NY 10021 (US). BHARDWAJ, Nina; 114 Upper Mountain Avenue, Montclair, NJ 07042 (US). STEINMAN, Ralph, M.; 62 North Avenue, Westport, CT 06880 (US). INABA, Kayo; Tanaka-Higashihinokuchi-cho 11-2, Sakyo, Kyoto 606-01 (JP).  <b>(74) Agents:</b> SONNENFELD, Kenneth, H. et al.; Morgan & Finnegan, L.L.P., 345 Park Avenue, New York, NY 10154 (US).	<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 29 December 1999 (29.12.99)	
<b>(54) Title:</b> APOPTOTIC CELL-MEDIATED ANTIGEN PRESENTATION TO DENDRITIC CELLS  <b>(57) Abstract</b>  This invention relates to methods and compositions useful for delivering antigens to dendritic cells which are then useful for inducing antigen-specific cytotoxic T lymphocytes and T helper cells. This invention also provides assays for evaluating the activity of cytotoxic T lymphocytes. According to the invention, antigens are targeted to dendritic cells by apoptotic cells which may also be modified to express non-native antigens for presentation to the dendritic cells. The dendritic cells which are primed by the apoptotic cells are capable of processing and presenting the processed antigen and inducing cytotoxic T lymphocyte activity or may also be used in vaccine therapies.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/03763

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C12N5/00 A61K39/00 A61K35/14 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 29182 A (THE ROCKEFELLER UNIVERSITY) 14 August 1997 (1997-08-14) cited in the application page 71 -page 75 ---	1,31,39
A	INABA K ET AL: "High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes." JOURNAL OF EXPERIMENTAL MEDICINE, (1997 AUG 29) 186 (5) 665-72. , XP002119452 cited in the application the whole document --- -/--	1-48

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

19 October 1999

Date of mailing of the international search report

03/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Moreau, J



# INTERNATIONAL SEARCH REPORT

Intern: al Application No

PCT/US 99/03763

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category <sup>2</sup>	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	INABA K ET AL: "Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells." JOURNAL OF EXPERIMENTAL MEDICINE, (1998 DEC 7) 188 (11) 2163-73. , XP002119453 the whole document ---	1-48
P,X	ALBERT, MATTHEW L. ET AL: "Resurrecting the dead: DCs cross-present antigen derived from apoptotic cells on MHC I" IMMUNOLOGIST (1998), 6(5), 194-198 , XP002119454 the whole document -----	1-48

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/03763

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark: Although claims 43-45 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.**
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

### Information on patent family members

Intern: \_\_\_\_\_ at Application No \_\_\_\_\_

PCT/US 99/03763

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9729182 A	14-08-1997	AU 1955997 A	28-08-1997
		EP 0914415 A	12-05-1999
-----			

